日本臨牀　別冊　免疫症候群(第2版)I

出版社： 日本臨牀社
発行日： 2015-11-20
分野： 臨床医学：一般  >  雑誌
ISSN： 471852
雑誌名：
特集： 免疫症候群（第2版）I―その他の免疫疾患を含めて―
電子書籍版： 2015-11-20 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
発送目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

目次

  • 日本臨牀　別冊　免疫症候群（第2版）I

    ―目次―

    特集　免疫症候群（第2版）I―その他の免疫疾患を含めて―

    I．臓器特異的自己免疫疾患
    　1　免疫性神経・筋疾患
    　2　自己免疫性内分泌疾患
    　3　自己免疫性血液疾患
    　4　自己免疫性消化器疾患(消化管，肝胆膵)
    　5　自己免疫性呼吸器疾患
    　6　自己免疫性腎・尿路疾患
    　7　自己免疫性皮膚疾患
    　8　自己免疫性眼疾患
    　9　その他

    II．全身性自己免疫疾患
    　1　全身性エリテマトーデス
    　2　関節リウマチ
    　3　多発性筋炎・皮膚筋炎
    　4　全身性強皮症
    　5　混合性結合組織病
    　6　重複症候群
    　7　抗リン脂質抗体症候群
    　8　Sj?gren症候群
    　9　ベーチェット病
    　10　再発性多発軟骨炎1
    　11　MAGIC症候群
    　12　好酸球性筋膜炎
    　13　Weber-Christian病
    　14　回帰性リウマチ
    　15　高γグロブリン血症性紫斑病
    　16　成人Still病
    　17　リウマチ性多発筋痛症
    　18　RS3PE 症候群
    　19　脊髄関節炎
    　20　サルコイドーシス
    　21　線維筋痛症(線維筋痛症候群)
    　22　慢性疲労症候群
    　23　リンパ腫様肉芽腫症
    　24　クリオフィブリノーゲン血症
    　25　アミロイドーシス
    　26　多中心性細網組織球症
    　27　Felty症候群
    　28　血管炎症候群
    　29　小児科領域における自己免疫疾患(小児期発症型)

    III．薬物・化学物質誘発性自己免疫疾患
    　1　薬剤誘発ループス
    　2　薬物・化学物質で引き起こされる皮膚硬化
    　3　薬剤性自己免疫性溶血性貧血
    　4　薬剤性自己免疫性好中球減少症
    　5　薬剤性再生不良性貧血

    IV．母体由来の自己抗体による新生児疾患
    　1　新生児一過性重症筋無力症
    　2　新生児甲状腺機能亢進症
    　3　新生児甲状腺機能低下症
    　4　同種免疫性新生児血小板減少症
    　5　新生児低血糖症
    　6　抗SS-A抗体症候群

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 臓器特異的自己免疫疾患

P.10 掲載の参考文献
1) Kappos L, et al : Atacicept in multiple sclerosis (ATAMS) : a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13 : 353-363, 2014.
PubMed
2) 富岳亮, 松井真 : 多発性硬化症の臨床病型と診断基準, 鑑別診断. 日本臨牀 72 : 1957-1963, 2014.
Medical*Online
3) Kinoshita M, et al : Natural history of clinically isolated syndrome on conversion to multiple sclerosis : A meta-analysis. P1.232, AAN Meeting, Philadelphia, 2014.
 
4) 田中正美ほか : 多発性硬化症に移行してから導入. 内科 107 : 150-153, 2011.
 
5) 田中正美 : 多発性硬化症へのナタリツマブ治療. 臨床神経 55 : 537-543, 2015.
 
6) 田中正美ほか : 多発性硬化症へのフィンゴリモド治療-どのように使用するか? 神経内科 76 : 390-397, 2012.
 
7) 田中正美 : フィンゴリモドの多発性硬化症への治療の進歩-2013年. 神経内科 79 : 400-410, 2013.
 
8) Havrdova E, et al : Freedom from disease activity in multiple sclerosis. Neurology 74 (Suppl 3) : S3-S7, 2010.
 
9) Imitola J, Racke MK : Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurol 72 : 145-147, 2015.
PubMed
10) Cohen JA, et al : Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362 : 402-415, 2010.
 
11) Rudick RA, et al : Natalizumab plus interferon beta-la for relapsing multiple sclerosis. N Engl J Med 354 : 911-923, 2006.
 
12) Khan O, et al : Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 73 : 705-713, 2013.
PubMed
13) Tanaka M, et al : Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia. Mult Scler 19 : 1244-1245, 2013.
PubMed
14) Tanaka M, Tanaka K : Dose reduction therapy of fingolimod for Japanese patients with multiple sclerosis : 24-months experience. Clin Exp Neuroimmunol 5 : 383-384, 2014.
 
15) Tanaka M, et al : Anti-JC Virus index in Japanese patients with multiple sclerosis and neuromyelitis optica related disorder. Clin Exp Neuroimmunol. (in press)
 
16) Tanaka M, et al : Body weight based natalizumab treatment in adult patients with multiple sclerosis. J Neurol 262 : 781-782, 2015.
PubMed
P.14 掲載の参考文献
1) Krupp LB, et al : Consensus definition proposed for pediatric multiple sclerosis and related disorders. Neurology 68 : S7-12, 2007.
 
2) 井上裕文, 市山高志 : 急性散在性脳脊髄炎. 最新アプローチ 多発性硬化症と視神経脊髄炎 (吉良潤一編), p104-108, 中山書店, 2012.
 
3) Torisu H, et al : Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev 32 : 454-462, 2010.
PubMed
4) Leake JA, et al : Acute disseminated encephalomyelitis in childhood : epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23 : 756-764, 2004.
PubMed
5) Zamvil SS, Steinman L : The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8 : 579-621, 1990.
 
6) Yoshitomi T, et al : Increased peripheral blood interferon gamma-producing T cells in acute disseminated encephalomyelitis. J Neuroimmunol 111 : 224-228, 2000.
PubMed
7) Brilot F, et al : Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66 : 833-842, 2009.
PubMed
8) Vanderlugt CL, Miller SD : Epitope spreading in immune-mediated diseases : implications for immunotherapy. Nat Rev Immunol 2 : 85-95, 2002.
PubMed
9) Tenembaum S, et al : Acute disseminated encephalomyelitis. Neurology 68 : S23-36, 2007.
PubMed
10) Schwarz S, et al : Acute disseminated encephalomyelitis : a follow-up study of 40 adult patients. Neurology 56 : 1313-1318, 2001.
PubMed
11) Dale RC, et al : Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis, and multiple sclerosis in children. Brain 123 : 2407-2422, 2000.
PubMed
12) 市山高志 : 急性散在性脳脊髄炎. 小児内科 36 : 1646-1649, 2004.
 
13) Ichiyama T, et al : Cerebrospinal fluid levels of cytokines and soluble tumor necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr 161 : 133-137, 2002.
PubMed
14) Callen DJ, et al : Role of MRI in differentiation of ADEM from MS in children. Neurology 72 : 968-973, 2009.
PubMed
15) スビヤントケイジ, 吉良龍太郎 : 急性散在性脳脊髄炎. 小児内科 45 : 398-401, 2013.
 
16) Nishikawa M, et al : Intravenous immunoglogulin therapy in acute disseminated encephalitis. Pediatr Neurol 21 : 583-586, 1999.
 
P.19 掲載の参考文献
1) Wingerchuk DM, et al : Spectrum neuromyelitis optica. Lancet Neurol 6 : 805-815, 2007.
PubMed
2) Sato DK, et al : Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82 (6) : 474-481, 2014.
PubMed
3) 玉腰暁子 : 全国疫学調査によるNMO患者の臨床像. 免疫性神経疾患に関する調査. 平成25年度総括・分担研究報告書, p80-89, 2014.
 
4) Lennon VA, et al : A serum antoantibody marker of neuromyelitis optica : distinction from multiple sclerosis. Lancet 364 : 2106-2112, 2004.
 
5) Lennon VA, et al : IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 : 473-477, 2005.
PubMed
6) Misu T, et al : Loss of aquaporin-4 in lesions of neuromyelitis optica : distinction from multiple sclerosis. Brain 130 (pt 5) : 1224-1234, 2007.
 
7) Takano R, et al : Astrocytic damage is far more severe than demyelination in NMO : a clinical CSF biomarker study. Neurology 75 : 208-216, 2010.
PubMed
8) Kinoshita M, et al : Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20 : 508-512, 2009.
PubMed
9) Uzawa A, et al : Cytokines and chemokines in neuromyelitis optica : pathogenic and therapeutic implications. Brain Pathol 24 (1) : 67-73, 2014.
 
11) Araki M, et al : Efficacy of the anti-IL-6 receptor antibody tocilizmab in neuromyelitis optica : a pilot study. Neurology 82 (15) : 1302-1306, 2014.
 
12) Papadopoulos MC, et al : Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11 : 535-544, 2012.
PubMed
13) Wingerchuk DM, et al : Revised diagnostic criteria for neuromyelitis optica. Neurology 66 : 1485-1489, 2006.
PubMed
14) Wingerchuk DM, et al : International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 : 177-189, 2015.
PubMed
15) Sato D, et al : Clinical spectrum and treatment of neuromyelitis optica spectrum disorders : evolution and current status. Brain Pathol 23 : 647-660, 2013.
PubMed
P.25 掲載の参考文献
1) Balo J : Encephalitis periaxialis concentrica. Arch Neurol Psychiatr 19 : 242-264, 1928.
 
2) Marburg O : Die sogenannte 'akute multiple Sklerose' (Encephalomyelitis periaxialis scleroticans). Jb Neurol Psychiatr 27 : 213-312, 1906.
 
3) Wang C, et al : Balo's disease showing benign clinical course and co-existence with multiple sclerosis-like lesions in Chinese. Mult Scler 14 : 418-424, 2008.
 
4) Wengert O, Siebert E : Images in clinical medicine. Balo's concentric sclerosis. N Engl J Med 365 : 742, 2011.
 
5) Graber JJ, et al : Neuromyelitis optica and concentric rings of Balo in the brainstem. Arch Neurol 66 : 274-275, 2009.
PubMed
6) Masuda H, et al : Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Balo's concentric lesions. Intern Med 52 (13) : 1517-1521, 2013.
 
7) Matsuoka T, et al : Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol 21 : 516-532, 2011.
PubMed
8) Kira J : Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis : astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci 311 : 69-77, 2011.
PubMed
9) Hardy TA, et al : Balo's concentric sclerosis and tumefactive demyelination : a shared immunopathogenesis? J Neurol Sci 348 : 279-281, 2015.
 
10) Hallervorden J, Spatz H : Uber die konzentrische Sklerose und die physikalisch-chemischen Faktoren bei der Ausbreitung von Entmarkungsprozessen. Arch Psychiat Nervenkr 98 : 641-701, 1933.
 
11) Stadelmann C, et al : Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 128 : 979-987, 2005.
 
12) Chitnis T, Hollmann TJ : CADASIL mutation and Balo concentric sclerosis : a link between demyelination and ischemia? Neurology 78 : 221-223, 2012.
PubMed
13) Chen CJ, et al : Serial magnetic resonance imaging in patients with Balo's concentric sclerosis : natural history of lesion development. Ann Neurol 46 : 651-656, 1999.
 
14) Kastrup O, et al : Balo's concentric sclerosis. Evolution of active demyelination demonstrated by serial contrast-enhanced MRI. J Neurol 249 : 811-814, 2002.
 
15) Pique J, et al : Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion. Mult Scler 21 : 1080-1083, 2015.
 
16) 田平武 : 同心円硬化症 (Balo). 別冊日本臨牀 神経症候群 II, p 423-426, 日本臨牀社, 1999.
 
17) Wiendl H, et al : Diffusion abnormality in Balo's concentric sclerosis : clues for the pathogenesis. Eur Neurol 53 : 42-44, 2005.
 
18) Kavanagh EC, et al : Diffusion-weighted imaging findings in Balo concentric sclerosis. Br J Radiol 79 : e28-e31, 2006.
PubMed
19) Chen CJ : Serial proton magnetic resonance spectroscopy in lesions of Balo concentric sclerosis. J Comput Assist Tomogr 25 : 713-718, 2001.
PubMed
20) Bolcaen J, et al : Structural and metabolic features of two different variants of multiple sclerosis : a PET/MRI study. J Neuroimaging 23 : 431-436, 2013.
PubMed
21) Berghoff M, et al : 7 Tesla MRI demonstrates vascular pathology in Balo's concentric sclerosis. Mult Scler 19 : 120-122, 2013.
 
22) Matsuoka T, et al : Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol 120 : 651-660, 2010.
 
23) Kira J : Astrocytopathy in Balo's disease. Mult Scler 17 : 771-779, 2011.
 
24) Masaki K, et al : Extensive loss of connexins in Balo's disease : evidence for an auto-antibodyindependent astrocytopathy via impaired astrocyte-oligodendrocyte/myelin interaction. Acta Neuropathol 123 : 887-900, 2012.
 
25) Lucchinetti C, et al : Heterogeneity of multiple sclerosis lesions : implications for the pathogenesis of demyelination. Ann Neurol 47 : 707-717, 2000.
PubMed
26) Long L, et al : Levamisole-induced leukoencephalopathy mimicking Balo disease. Neurology 84 : 328, 2015.
PubMed
P.29 掲載の参考文献
1) Kira J, et al : Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 148 : 199-203, 1997.
PubMed
2) Osoegawa M, et al : Myelitis with atopic diathesis : a nationwide survey of 79 cases in Japan. J Neurol Sci 209 : 5-11, 2003.
PubMed
3) Isobe N, et al : Neural damage associated with atopic diathesis : a nationwide survey in Japan. Neurology 73 : 790-797, 2009.
PubMed
4) Zoli A, et al : Atopic myelitis : first case report outside Japan? Allergy 60 : 410-411, 2005.
PubMed
5) Yoon JH, et al : Clinical and laboratory characteristics of atopic myelitis : Korean experience. J Neurol Sci 285 : 154-158, 2009.
PubMed
6) Isobe N, et al : First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis. J Neurol Sci 316 : 30-35, 2012.
PubMed
7) Kikuchi H, et al : Spinal cord lesions of myelitis with hyperIgEemia and mite antigen specific IgE (atopic myelitis) manifest eosinophic inflammation. J Neurol Sci 183 : 73-78, 2001.
 
8) Osoegawa M, et al : Eosinophilic myelitis associated with atopic diathesis : a combined neuroimaging and histopathological study. Acta Neuropathol 105 : 289-295, 2003.
PubMed
9) Sato S, et al : HLA-DPB1 *0201 is associated with susceptibility to atopic myelitis in Japanease. J Neuroimmunol 251 : 110-113, 2012.
 
10) Tanaka M, et al : Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71 : 974-981, 2008.
PubMed
11) Murai H, et al : Effect of immunotherapy in myelitis with atopic diathesis. J Neurol Sci 227 : 39-47, 2004.
PubMed
P.34 掲載の参考文献
1) Transverse Myelitis Consortium Working Group : Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 59 : 499-505, 2002.
 
2) Berman M, et al : Acute transverse myelitis : incidence and etiologic considerations. Neurology 31 : 966-971, 1981.
PubMed
3) Abramsky O, Teitolbaum D : The autoimmune features of acute transverse myelopathy. Ann Neurol 12 : 36-40, 1977.
 
4) Arlazoroff A, et al : Acut transverse myelitis, a possible vascular etiology. Med Hypotheses 30 : 27-30, 1989.
 
5) Endo A, et al : A case of acute transverse myelitis due to measles virus. Journal of Pediatric Infectious Diseases 4 : 405-408, 2009.
 
6) 阿部百合子ほか : ムンプス後横断性脊髄炎の1男児例. 小児科医会報 25 : 1-5, 2007.
 
7) Holtas S, et al : MRI in acute transverse myelopathy. Neuroradiology 35 : 221-226, 1993.
PubMed
8) Breningstall GN, Belani KK : Acute transverse myelitis and brainstem encephalitis associated with hepatitis A infection. Pediatr Neurol 12 : 169-171, 1995.
PubMed
9) Sanders KA, et al : Gadolinium-MRI in acute transverse myelopathy. Neurology 40 : 1614-1616, 1990.
PubMed
10) Scott TF, et al : Evidence-based guideline : clinical evaluation and treatment of transverse myelitis : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 77 : 2128-2134, 2011.
PubMed
11) 笠井肇 : 免疫グロブリン大量療法が奏効した急性横断性脊髄炎の1例. 脳と発達 28 : 354-356, 1996.
 
12) Paine RS, Byers RK : Transverse myelopathy in childhood. Am J Dis Child 85 : 151-163, 1953.
 
13) Miyazawa R, et al : Determinants of prognosis of acute transverse myelitis in children. Pediatr Int 45 : 512-516, 2003.
PubMed
14) Dunne K et al : Acute transverse myelopathy in children. Dev Med Child Neurol 28 : 198-204, 1986.
PubMed
P.39 掲載の参考文献
1) Saida T, et al : Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 204 : 1103-1106, 1979.
PubMed
2) Kusunoki S, et al : Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39 : 424-431, 1996.
PubMed
3) Susuki K, et al : Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27 : 3956-3967, 2007.
PubMed
4) van Belkum A, et al : Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med 7 : 752-753, 2001.
PubMed
5) Kaida K, et al : GD1b-specific antibody induces ataxia in Guillain-Barre syndrome. Neurology 71 : 196-201, 2006.
 
6) Kaida K, et al : Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182 : 212-218, 2007.
PubMed
7) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet 349 : 225-230, 1997.
PubMed
8) van Koningsveld R, et al ; Dutch GBS study group : Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome : randomised trial. Lancet 17 : 192-196, 2004.
 
9) Walgaard C, et al : Prediction of respiratory insufficiency in Guillain-Barre syndrome. Ann Neurol 67 : 781-787, 2010.
PubMed
P.42 掲載の参考文献
1) Fisher M : An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255 : 57-65, 1956.
PubMed
2) Mitsui Y, et al ; Japanese GBS Study Group : A multicentre prospective study of Guillain-Barre syndrome in Japan : a focus on the incidence of subtypes, J Neurol Neurosurg Psychiatry 86 : 110-114, 2015.
 
3) Mori M, et al : Clinical features and prognosis of Miller Fisher syndrome. Neurology 56 : 1104-1106, 2001.
PubMed
4) Koga M, et al : Antecedent infections in Fisher syndrome : a common pathogenesis of molecular mimicry. Neurology 64 : 1605-1611, 2005.
PubMed
5) Chiba A, et al : Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31 : 677-679, 1992.
PubMed
6) Koga M, et al : Miller Fisher syndrome and Haemophilus innuenza infection. Neurology 57 : 686-691, 2001.
PubMed
7) Yuki N, et al : Molecularmimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 36 : 791-793, 1994.
 
8) Mori M, Kuwabara S : Fisher syndrome. Curr Treat Options Neurol 13 : 71-78, 2011.
PubMed
9) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
10) Kusunoki S, et al : Anti-GQ1b antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 22 : 1071-1074, 1999.
PubMed
11) Kaida K, et al : Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 77 : 1043-1046, 2006.
PubMed
12) ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013 (「ギラン・バレー症候群, フィッシャー症候群診療ガイドライン」作成委員会編), p176-177, 南江堂, 2013.
 
P.48 掲載の参考文献
1) Lawson VH, Arnold WD : Multifocal motor neuropathy : a review of pathogenesis, diagnosis, and treatment. Neuropsychiatr Dis Treat 10 : 567-576, 2014.
PubMed
2) Miyashiro A, et al : Are multifocal motor neuropathy patients underdiagnosed? An epidemiological survey in Japan. Muscle Nerve 49 : 357-361, 2014.
PubMed
3) Cats EA, et al : Correlates of outcome and response to Mg in 88 patients with multifocal motor neuropathy. Neurology 75 : 818-825, 2010.
PubMed
4) Nobile-Orazio E : Multifocal motor neuropathy. J Neuroimmunol 115 : 4-18, 2001.
PubMed
5) Kaji R et al : Pathological findings at the site of conduction block in multifbcal motor neuropathy. Ann Neurol 33 : 152-158, 1993.
PubMed
6) Taylor BV, et al : Multifocal motor neuropathy : pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 63 : 129-137, 2004.
PubMed
7) Straver DC, et al : Cold paresis in multifocal motor neuropathy. J Neurol 258 : 212-217, 2011.
PubMed
8) Joint Task Force of the EFNS and the PNS : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 15 : 295-301, 2010.
PubMed
9) Van Es HW, et al : Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy. Neurology 48 : 1218-1224, 1997.
PubMed
10) Pitarokoili K, et al : Nerve ultrasound in a case of multifocal motor neuropathy without conduction block. Muscle Nerve 52 : 294-299, 2015.
 
11) Grimm A, et al : Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy. J Neurol 262 : 870-880, 2015.
PubMed
12) 園生雅弘 : 末梢神経疾患の電気診断 : 脱髄性ニューロパチーを中心に. 末梢神経 23 (2) : 215-223, 2012.
Medical*Online
13) van Schaik IN, et al : Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev (2) : CD004429, 2005.
PubMed
14) Terenghi F, et al : How long is rVIg effective in multifocal motor neuropathy? Neurology 62 : 666-668, 2004.
 
15) Umapathi T, et al : Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev 3 : CD003217, 2015.
PubMed
P.52 掲載の参考文献
1) Lewis RA, et al : Multifocal demyelinating neuropathy with persistent conduction block. Neurology 32 : 958-964, 1982.
PubMed
2) 東琢哉, 田代邦雄 : Lewis-Sumller症候群. 別冊日本臨牀 免疫症候群 (上), p 39-43, 日本臨牀社, 2000.
 
3) Oh SJ, et al : Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy) : a separate entity or a variant of chronic innammatory demyelinating polyneuropathy? J Peripher Nerv Syst 2 : 362-3 69., 1997.
PubMed
4) Van den Berg-Vos RM, et al : Multifocal inflammatory demyelinating neuropathy : a distinct clinical entity? Neurology 54 : 26-32, 2000.
PubMed
5) Lewis RA : Multifocal motor neuropathy and Lewis Sumner syndrome : two distinct entities. Muscle Nerve 22 : 1738-1739, 1999.
PubMed
6) Parry GJ : Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities? Muscle Nerve 22 : 557-559, 199 9.
 
7) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 41 : 617-618, 1991.
PubMed
8) Van den Bergh PY, et al : European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 17 : 356-363, 2010.
PubMed
9) Rajabally YA, et al : Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria : study of a UK population. Muscle Nerve 39 : 432-438, 2009.
PubMed
10) Iijima M, et al : Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 79 : 1040-1043, 2008.
PubMed
11) Kuwabara S, et al : Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86 : 1054-1059, 2015.
PubMed
12) Vallat JM, et al : Chronic inflammatory demyelinating polyradiculoneuropathy : diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 9 : 402-412, 2010.
PubMed
13) Saperstein DS, et al : Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 24 : 311-324, 2001.
PubMed
14) Viala K, et al : Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127 : 2010-2017, 2004.
PubMed
15) Verschueren A, et al : Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve 31 : 88-94, 2005.
PubMed
16) Allen DC, et al : Multifocal acquired demyelinating sensory and motor neuropathy presenting as a peripheral nerve tumor. Muscle Nerve 34 : 373-379, 2006.
PubMed
17) Saperstein DS, et al : Multifocal acquired demyelinating sensory and motor neuropathy : the Lewis-Sumner syndrome. Muscle Nerve 22 : 560-566, 1999.
PubMed
18) Rajabally YA, et al : Diagnostic value of MR imaging in the Lewis-Sumner syndrome : a case series. J Neurol Sci 342 : 182-185, 2014.
 
19) Scheidl E, et al : Ultrasonography of MADSAM neuropathy : focal nerve enlargements at sites of existing and resolved conduction blocks. Neuromuscul Disord 22 : 627-631, 2012.
PubMed
20) Kerasnoudis A, et al : Bochum ultrasound score allows distinction of chronic inflammatory from multifocal acquired demyelinating polyneuropathies. J Neurol Sci 348 : 211-215, 2015.
PubMed
21) Olney RK : Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl 8 : S225-229, 1999.
 
22) Nobile-Orazio E, et al : Multifocal motor neuropathy : current concepts and controversies. Muscle Nerve 31 : 663-680, 2005.
PubMed
23) 園生雅弘 : 末梢神経疾患の電気診断 : 脱髄性ニューロパチーを中心に. 末梢神経 23 : 215-223, 2012.
Medical*Online
24) Kuwabara S, et al : Long term prognosis of chronic inflammatory demyelinating polyneuropathy : a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77 : 66-70, 2006.
 
25) Hughes RA, et al : Controlled trial prednisolone in acute polyneuropathy. Lancet 2 : 750-753, 1978.
PubMed
P.59 掲載の参考文献
1) Dyck PJ, et al : Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50621-637, 1975.
 
2) Iijima M, et al : Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. Peripheral Neuropathy Study Group of Japan. J Neurol Neurosurg Psychiatry 79 : 1040-1043, 2008.
 
3) Dalakas MC : Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7 : 507-517, 2011.
PubMed
4) Querol L, et al : Neurofascin IgG4 antibodies in CIDP associated with disabling tremor and poor response to IVIg. Neurology 82 : 879-886, 2014.
PubMed
5) Querol L, et al : Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73 : 7907-7918, 2013.
 
6) 日本神経学会 : 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013 (慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン作成委員会編), 南江堂, 2013.
 
7) Mori K, et al : Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58 : 979-982, 2002.
PubMed
8) Bird SJ, et al : Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 46 : 822-824, 1996.
PubMed
9) Briani C, et al : Spectrum of paraneoplastic disease associated with lymphoma. Neurology 76 : 705-710, 2011.
PubMed
10) Antonie JC, et al : Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 49 : 214-221, 2001.
 
11) Ginsberg L, et al : Coexistent hereditary and inflammatory neuropathy. Brain 127 : 193-202, 2004.
PubMed
12) Hughes R, et al : Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 : 195-201, 2001.
PubMed
13) Dyck PJ, et al : A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36 : 838-845, 1994.
PubMed
14) Latov N, et al : Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy, Arch Neurol 67 : 802-807, 2010.
PubMed
15) Kuwabara S, et al : Long term prognosis of chronic infiammatory demyelinating polyneuropathy : a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77 : 66-70, 2006.
 
P.63 掲載の参考文献
1) 千葉厚郎 : MAG抗体陽性ニューロパチー. 別冊日本臨牀 神経症候群 II, p851-855, 日本臨牀社, 2014.
 
2) Kawagashira Y, et al : Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy. J Neuropathol Exp Neurol 69 : 1143-1157, 2010.
PubMed
3) Steck AJ, et al : Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 19 : 458-463, 2006.
 
4) Shiina M, et al : Variability in immunohistochemistries of IgM M-proteins binding to sulfated glucuronyl paragloboside. J Neuroimmunol 116 : 206-212, 2001.
PubMed
5) Brouet JC, et al : Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides. Clin Exp Immunol 96 : 466-469, 1994.
PubMed
6) Hellqvist E, et al : Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype : aberrant triggering of a patient's T cells. Haematologica 95 : 627-636, 2010.
 
7) Latov N : Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 37 Suppl 1 : S32-42, 1995.
PubMed
8) Ilyas AA, et al : Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 193 : 87-93, 2008.
PubMed
9) Luigetti M, et al : Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy. J Neurol Sci 319 : 75-80, 2012.
 
10) Kuijf ML, et al : Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73 : 688-695, 2009.
PubMed
11) Attarian S, et al : Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol 112 : 457-463, 2001.
PubMed
12) Magy L, et al : Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies. J Immunol Res 2015 : 450391, 2015.
PubMed
13) Lombardi R, et al : IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann Neurol 57 : 180-187, 2005.
PubMed
14) Lunn MP, Nobile-Orazio E : Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 5 : CD002827, 2012.
PubMed
15) Niermeijer JM. et al : Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 69 : 50-59, 2007.
PubMed
16) Leger JM, et al : Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80 : 2217-2225, 2013.
PubMed
17) Hospital MA, et al : Immunotherapy-based regimen in anti-MAG neuropathy : results in 45 patients. Haematologica 98 : e155-157, 2013.
PubMed
18) Niermeijer JM, et al : Prognosis of polyneuropathy due to IgM monoclonal gammopathy : a prospective cohort study. Neurology 74 : 406-412, 2010.
PubMed
19) Hamada Y. et al : Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy : possible clinical relevance. Neurosci Res 91 : 63-68, 2015.
PubMed
P.69 掲載の参考文献
1) Kuwabara S, et al : Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev (4) : CD006828, 2008.
PubMed
2) Nakanishi T, et al : The Crow-Fukase syndrome : a study of 102 cases in Japan. Neurology 34 : 712-720, 1984. .
PubMed
3) 納光弘ほか : Crow-Fukase症候群の全国疫学調査 2004. 厚生労働省免疫性神経疾患に関する調査研究班平成16年度報告書, p141-144, 2004.
 
4) Watanabe O, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996.
PubMed
5) Abe D, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839 , 2008.
PubMed
6) Kuwabara S, et al : Long term melphalan-prednisolone chemotherapy for POEMS syndrome. Neurol Neurosurg Psychiatry 63 : 385-387, 1997.
PubMed
7) 桑原聡, 三澤園子 : Crow-Fukase症候群の新規治療展望. Annual Review神経 2007, p 214-220, 中外医学社, 2007.
 
8) Wong VA, Wade NK : POEMS syndrome : an unusual cause of bilateral optic disk swelling. Am J Ophthalmol 126 : 452-454, 1998.
PubMed
9) Jaccard A, et al : High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood 99 : 3057-3059, 2002.
PubMed
10) Dispenzieri A, et al : Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 104 : 3400-3407, 2004.
 
11) Kuwabara S, et al : Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology 66 : 105-107, 2006.
PubMed
12) Kuwabara S, et al : Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 71 : 1691-1695, 2008.
PubMed
13) Kuwabara S, et al : Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry 79 : 1255-1257, 2008.
PubMed
14) Dispenzieri A, et al : Lenalidomide therapy in a patient with POEMS syndrome. Blood 110 : 1075-1076, 2007.
 
15) Kanai K, et al : Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 46 : 311-313, 2007.
PubMed
P.74 掲載の参考文献
1) Koike H, et al : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013.
PubMed
2) Koike H, Sobue G : The wide range of clinicopathological features in immune-mediated autonomic neuropathies. Clin Exp Neuroimmunol 4 : 46-59, 2013.
 
3) Koike H, et al : Clinicopathological features of acute autonomic and sensory neuropathy. Brain 133 : 2881-2896, 2010.
PubMed
4) Colan RV, et al : Acute autonomic and sensory neuropathy. Ann Neurol 8 : 441-444, 1980.
PubMed
5) Pavesi G, et al : Acute sensory and autonomic neuropathy : possible association with coxsackie Bvirus infection. J Neurol Neurosurg Psychiatry 55 : 613-615, 1992.
 
6) Bennett JL, et al : Epstein-Barr virus-associated acute autonomic neuropathy. Ann Neurol 40 : 453-455, 1996.
PubMed
7) Fagius J, et al : Acute pandysautonomia and severe sensory deficit with poor recovery. A clinical, neurophysiological and pathological case study. J Neurol Neurosurg Psychiatry 46 : 725-733, 1983.
PubMed
8) Irioka T, et al : Acute autonomic and sensory neuropathy after interferon alpha-2b therapy for chronic hepatitis C. J Neurol Neurosurg Psychiatry 70 : 408-410, 2001.
PubMed
9) Tohgi H, et al : Acute autonomic and sensory neuropathy : report of an autopsy case. Acta Neuropathol 77 : 659-663, 1989.
PubMed
10) Kurokawa K et al : A case of pandysautonomia with associated sensory ganglionopathy. J Neurol Neurosurg Psychiatry 65 : 278-279, 1998.
PubMed
11) Kanda F, et al : Acute autonomic and sensory neuropathy : a case report. J Neurol 237 : 42-44, 1990.
PubMed
12) Mori K, et al : The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain 128 : 2518-2534, 2005.
 
13) Vernino S, et al : Invited Article : Autonomic ganglia : target and novel therapeutic tool. Neurology 70 : 1926-1932, 2008.
PubMed
14) Koike H, et al : The spectrum of clinicopathological features in pure autonomic neuropathy. J Neurol 259 : 2067-2075, 2012.
PubMed
15) Ohyama K, et al : Differential recovery in cardiac and vasomotor sympathetic functional markers in acute autonomic sensory and motor neuropathy : a case report. Intern Med 52 : 497-502, 2013.
PubMed
P.81 掲載の参考文献
1) Koike H, et al : The spectrum of immune-mediated autonomic neuropathies : insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 84 : 98-106, 2013.
PubMed
2) Vernino S, et al : Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50 : 1806-1813, 1998.
PubMed
3) Vernino S, et al : Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343 : 847-855, 2000.
PubMed
4) Vernino S, et al : Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 146 : 3-7, 2009.
 
5) Higuchi O, et al : Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69 : 418-422, 2011.
PubMed
6) Nakane S, et al : Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One 10 (3) : e0118312, 2015.
PubMed
7) Lennon VA, et al : Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 111 : 907-913, 2003.
PubMed
8) Vernino S, et al : Experimental autoimmune autonomic neuropathy. J Neurophysiol 90 : 2053-2059, 2003.
PubMed
9) Vernino S, et al : Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci 24 : 7037-7042, 2004.
PubMed
10) Wang Z, et al : Antibody-mediated impairment and homeostatic plasticity of autonomic ganglionic synaptic transmission. Exp Neurol 222 : 114-119, 2010.
PubMed
11) Wang Z, et al : Autoimmune autonomic ganglionopathy : IgG effects on ganglionic acetylcholine receptor current. Neurology 68 : 1917-1921, 2007.
PubMed
12) Iodice V, et al : Immunotherapy for autoimmune autonomic ganglionopathy. Auton Neurosci 146 : 22-25, 2009.
PubMed
13) Winston N, Vernino S : Recent advances in autoimmune autonomic ganglionopathy. Curr Opin Neurol 23 : 514-518, 2010.
PubMed
14) Nishihara H, et al : Combined immunomodulatory therapies resulted in stepwise recovery in autoimmune autonomic ganglionopathy. Clin Exp Neuroimmunol. doi : 10.1111/cen3.12137, 2014.
 
15) Gibbons CH, et al : Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 65 : 213-217, 2008.
PubMed
16) Goldstein DS, et al : Clinical laboratory evaluation of autoimmune autonomic ganglionopathy : Preliminary observations. Auton Neurosci 146 : 18-21, 2009.
PubMed
P.87 掲載の参考文献
1) Meriggioli MN, Sanders DB : Autoimmune myasthenia gravis : emerging clinical and biological heterogeneity. Lancet Neurol 8 : 475-490, 2009.
PubMed
2) 重症筋無力症診療ガイドライン (日本神経学会 (監), 「重症筋無力症診療ガイドライン」作成委員会 (編)), 南江堂, 2014.
 
3) Suzuki S, et al : Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry 84 : 989-994, 2013.
PubMed
4) Suzuki S, et al : Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66 : 1334-1338, 2009.
PubMed
P.91 掲載の参考文献
1) Murai H, et al : Characteristics of myasthenia gravis according to onset-age : Japanese nationwide survey. J Neurol Sci 305 : 97-102. 2011.
PubMed
2) 小児期発症MG. 重症筋無力症診療ガイドライン 2014 (「重症筋無力症診療ガイドライン」作成委員会編), p114-139, 南江堂, 2014.
 
3) 瀬川昌也 : 小児重症筋無力症-潜在性全身型. 内科 31 : 1222-1226, 1973.
 
4) 苛原香ほか : 本邦における先天性筋無力症候群の臨床特徴. 脳と発達 44 : 450-454, 2012.
 
5) 白石一浩 : 重症筋無力症. 小児の治療指針. 小児科臨床 2014年増刊号 (井田博幸編), p821-824, 診断と治療社, 2014.
 
6) Munsat TL : Anticholinesterase abuse in myasthenia gravis. J Neurol Sci 64 : 5-10, 1984.
PubMed
7) Mori T, et al : Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus. Brain Dev 35 : 445-448, 2013.
PubMed
P.97 掲載の参考文献
1) 出雲周二ほか : HAM患者の全国疫学予備調査の報告. 免疫性神経疾患に関する調査研究班平成21年度総括・分担研究報告書 2010, p103-106.
 
2) Jeffery KJ, et al : HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 96 : 3848-3853, 1999.
PubMed
3) Olindo S, et al : Natural history of human T-lymphotropic virus 1-associated myelopathy : a 14-year follow-up study. Arch Neurol 63 : 1560-1566, 2006.
PubMed
4) Nakamura T : HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) : the role of HTLV-O-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol 47 : 182-194, 2009.
 
5) Araya N, et al : HTLV-I induces a Th1-like state in CD4+ CCR4+ T cells. J Clin Invest 124 : 3431-3442, 2014.
 
6) Matsuura E, et al : Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neuropathol Exp Neurol 74 : 2-14, 2014.
 
7) Ando H, et al : Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136 : 2876-2887, 2013.
PubMed
8) Castro NM, et al : Urinary symptoms associated with human T-cell lymphotropic virus type I infection : evidence of urinary manifestations in large group of HTLV-I carriers. Urology 69 : 813-818, 2007.
 
9) Sato T, et al : CSF CXCL10, CXCL9. and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 7 : e2479, 2013.
PubMed
10) Yukitake M, et al : Incidence and clinical significances of human T-cell lymphotropic virus type I-associated myelopathy with T2 hyperintensity on spinal magnetic resonance images. Intern Med 47 : 1881-1886, 2008.
 
11) Puccioni-Sohler M, et al : Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-1. Neurology 68 : 206-213, 2007.
PubMed
12) Nakamura T, et al : Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cent Nerv Syst Agents Med Chem 9 : 137-149, 2009.
PubMed
13) Nakagawa M, et al : Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2 : 345-355, 1996.
PubMed
14) Izumo S, et al : Interferon alpha is effective in HTLV-I-associated myelopathy : a multicenter, randomized, double-blind, controlled trial. Neurology 46 : 1016-1021, 1996.
PubMed
15) Kataoka A, et al : Intermittent highdose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 56 : 1213-1216, 1993.
 
P.101 掲載の参考文献
1) Brain L, et al : Hashimoto's disease and encephalopathy. Lancet ii : 512-514, 1966.
 
2) Shaw PJ, et al : Hashimoto's encephalopathy : a steroid-responsive disorder associated with anti-thyroid antibody titers-report of 5 cases. Neurology 41 : 228-233, 1991,
 
3) Ferracci F, et al : Hashimoto's encephalopathy : epidemiologic data and pathogenetic considerations. J Neurol Sci 217 : 165-168, 2004.
 
4) Fujii A, et al : Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy. J Neuroimmunol 162 : 130-136, 2005.
 
5) Yoneda M, et al : High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. J Neuroimmunol 185 : 195-200, 2007.
 
6) Mitoma H, et al : Presynaptic dysfunction caused by CSF from a patient with ataxic form of Hashimoto's encephalopathy. Neurol Clin Neurosci 2 : 104-108, 2014.
 
7) Oide T, et al : Anti-neuronal autoantibody in Hashimoto's encephalopathy : neuropathological, immunohistochemical, and biochemical analysis of two patients. J Neurol Sci 217 : 7-12, 2004.
 
8) Helene V, et al : Hashimoto encephalopathy and antibodies against dimethylargininase-1 : a rare cause of cognitive decline in a pediatric Down's syndrome patient. Clin Neurol Neurosurg 113 : 678-679, 2011.
 
9) Gini B, et al : Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach. J Neuroimmunol 196 : 153-158. 2008.
 
10) Nolte KW, et al : Hashimoto encephalopathy : a brainstem vasculitis? Neurology 54 : 769-770, 2000.
PubMed
11) Kothbauer-Margreiter I, et al : Encephalopathy asg. ociated with Hashimoto thyroiditis : diagnosis and treatment, J Neurol 243 : 585-593, 1996.
 
12) Matsunaga A, et al : Hashimoto's encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol 69 : 14-20, 2012.
 
13) Peschen-Rosin R, et al : Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 41 : 79-84, 1999.
 
14) Muramatsu T, et al : Pathophysiological decrease in the regional cerebral blood flow in Hashimoto's encephalopathy : amultiple-case. Eur Neurol 72 : 10-13, 2014.
 
15) Boers PM, Colebatch JG : Hashimoto's encephalopathy responding to plasmapheresis. J Neurol Neurosurg Psychiatry 70 : 132, 2001.
 
P.106 掲載の参考文献
1) 西村敏樹ほか : 無菌性非ヘルペスウイルス性急性脳炎の病態-若年女性に起こり, 強い意識障害と遷延経過を示すが転帰比較的良好な1群について-. Neuroinfection 2 : 74-76, 1997.
 
2) 亀井聡 : 若年女性に好発する急性非ヘルペス性脳炎 (Acute Juvenile Female Non-Herpetic Encephalitis : AJFNHE). 神経研究の進歩 48 : 827-836, 2004.
 
3) Dalmau J, et al : Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61 : 25-36, 2007.
PubMed
4) Iizuka T, et al : Anti-NMDA receptor encephalitis in Japan. Long-term outcome without tumor removal. Neurology 70 : 504-511, 2008.
PubMed
5) Kamei S, et al : Nationwide survey of acute juvenile female non-herpetic encephalitis in Japan : relationship to anti-N-methyl-D-aspartate receptor encephalitis. Intern Med 48 : 673-679, 2009.
PubMed
6) Titulaer MJ, et al : Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study. Lancet Neurol 12 : 157-165, 2013.
PubMed
7) Hara M, et al : Anti-N-methyl-D-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. J Neurol 258 : 1351-1353, 2011.
PubMed
8) Dalmau J, et al : Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 7 : 1091-1098, 2008.
PubMed
9) Planaguma J, et al : Human N-methyl-D-aspartate receptor antibodies alter memory and behavior in mice. Brain 138 : 94-109, 2015.
 
10) Hughes EG, et al : Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30 : 5866-5875, 2010.
PubMed
11) Dalmau J, et al : Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10 : 63-74, 2011.
PubMed
12) Gleichman AJ, et al : Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci 32 : 11082-11094, 2012.
PubMed
13) Mikasova L, et al : Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain 135 : 1606-1621, 2012.
PubMed
14) Armangue T, et al : Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 162 : 850-856, 2013.
 
15) Schmitt SE, et al : Extreme delta brush : a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79 : 1094-1100, 2012.
 
16) Iizuka T, et al : Reversible brain atrophy in anti-NMDA receptor encephalitis : a long-term observational study. J Neurol 257 : 1686-1691, 2010.
PubMed
17) Lai M, et al : Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels : a case series. Lancet Neurol 9 : 776-785, 2010.
PubMed
18) Irani SR, et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
19) Lai M, et al : AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65 : 424-434, 2009.
PubMed
20) Lancaster E, et al : Antibodies to the GABA (B) receptor in limbic encephalitis with seizures : case series and characterisation of the antigen. Lancet Neurol 9 : 67-76, 2010.
PubMed
21) Tham SL, et al : A case of anti-NMDAR (N-methyl-D-aspartate receptor) encephalitis : a rehabilitation perspective. NeuroRehabilitation 30 : 109-112, 2012,
PubMed
22) Gabilondo I, et al : Analysis of relapses in anti-NMDAR encephalitis. Neurology 77 : 996-999, 2011.
PubMed
P.111 掲載の参考文献
1) Buckley C, et al : Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50 : 73-78, 2001.
PubMed
2) Vincent A, et al : Potassium channel antibody-associated encephalopathy : apotentially immunotherapy-responsive form of limbic encephalitis. Brain 127 : 701-712, 2004.
 
3) Thieben MJ, et al : Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 : 1177-1182, 2004.
PubMed
4) Lai M, et al : Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels : a case series. Lancet Neurol 9 : 776-785, 2010.
PubMed
5) Irani SR, et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactived 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
6) Lancaster E, et al : Encephalitis and antibodies to synaptic and neuronal cell surface protein. Neurology 77 : 179-189, 2011.
PubMed
7) Irani SR, et al : Morvan syndrome : Clinical and serological observations in 29 cases. Ann Neurol 72 (2) : 241-255, 2012.
PubMed
8) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
9) Irani SR, et al : Cell-surface central nervous system antibodies : clinical relevance and emerging paradigms. Ann Neurol 76 : 168-184, 2014.
PubMed
10) Ohkawa T, et al : Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Nuerosci 33 (46) : 18161-18174, 2013.
 
11) Ohkawa T, et al : Identification and characterization of GABAA receptor autoantibodies in autoimmune encephalitis. J Neurosci 34 (24) : 8151-8163, 2014.
PubMed
12) Irani SR, et al : Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69 : 892-900, 2011.
PubMed
13) Butler CR, et al : Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex. J Neurol Neurosurg Psychiatry 85 (4) : 387-391, 2014.
PubMed
P.116 掲載の参考文献
1) Bien CG, et al : The natural history of Rasmussen's encephalitis. Brain 125 : 1751-1759, 2002.
 
2) Bien CG, et al : Pathogenesis, diagnosis and treatment of Rasmussen encephalitis : a European consensus statement. Brain 128 : 454-471, 2005.
PubMed
3) Bien CG, et al : Rasmussen encephalitis : Incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 54 : 543-550, 2013.
PubMed
4) 高橋幸利ほか : Rasmussen症候群. 小児内科 45 : 416-421, 2013.
Medical*Online
5) Amrom D, et al : Rasmussen encephalitis and comorbid autoimmune diseases. A window into disease mechanism? Neurology 83 : 1049-1055, 2014.
PubMed
6) Takahashi Y, et al : Vaccination and infection as causative factors in Japanese patients with Rasmussen syndrome : molecular mimicry and HLA class I. Clin Dev Immunol 13 : 381-387, 2006.
 
7) Bien CG, et al : Destruction of neurons by cytotoxic T cells : a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 51 : 311-318, 2002.
 
8) Li Y, et al : Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. J Immunol 158 : 1428-1437, 1997.
 
9) Korn-Lubetzki I, et al : Rasmussen encephalitis with active inflammation and delayed seizures onset. Neurology 62 : 984-986, 2004.
PubMed
10) Pardo CA, et al : The pathology of Rasmussen syndrome : stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 45 : 516-526, 2004.
PubMed
11) Vining EP, et al : Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience : 1968 to 1996. Pediatrics 100 : 163-171, 1997.
 
12) Pulsifer MB, et al : The cognitive outcome of hemispherectomy in 71 children. Epilepsia 45 : 243-254, 2004.
PubMed
13) Terra-Bustamante VC, et al : Rasmussen encephalitis : long-term outcome after surgery. Childs Nerv Syst 25 : 583-589, 2009.
PubMed
14) Muto A, et al : Nationwide survey (incidence, clinical course, prognosis) of Rasmussen's encephalitis. Brain Dev 32 : 445-453, 2010.
 
15) Oguni H, et al : The syndrome of chronic encephalitis and epilepsy. A study based on the MNI series of 48 cases. Adv Neurol 57 : 419-433, 1992.
PubMed
P.120 掲載の参考文献
1) Lai M, et al : AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65 : 424-434, 2009.
PubMed
2) Rogers SW, et al : Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 : 648-651, 1994.
 
3) Wiendl H, et al : GluR3 antibodies : prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57 : 1511-1514, 2001.
 
4) Granerod J, et al : Causes of encephalitis and differences in their clinical presentations in England : a multicentre, population-based prospective study. Lancet Infect Dis 10 : 835-844, 2010.
 
5) Bataller L, et al : Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74 : 265-267, 2010.
PubMed
6) Dogan Onugoren M, et al : Limbic encephalitis due to GABAB and AMPA receptor antibodies : a case series. J Neurol Neurosurg Psychiatry 86 : 965-972, 2015.
 
7) Spatola M, et al : Serial brain 18FDG-PET in anti-AMPA receptor limbic encephalitis. J Neuroimmunol 271 : 53-55, 2014.
PubMed
8) Wei YC, et al : Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 261 : 129-133, 2013.
PubMed
9) Graus F, et al : Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 257 : 509-517, 2010.
PubMed
10) Elamin M, et al : Posterior cortical and white matter changes on MRI in anti-AMPA receptor antibody encephalitis. Neurol Neuroimmunol Neuroinflamm 2 : e118, 2015.
PubMed
11) Li X, et al : Anti-AMPA receptor encephalitis associated with thymomatous myasthenia gravis. J Neuroimmunol 281 : 35-37, 2015.
PubMed
12) Hoftberger R, et al : Encephalitis and AMPA receptor antibodies : Novel findings in a case series of 22 patients. Neurology 84 : 2403-2412, 2015.
 
13) Traynelis SF, et al : Glutamate receptor ion channels : structure, regulation, and function. Pharmacol Rev 62 : 405-496, 2010.
PubMed
14) Peng X, et al : Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 77 : 381-398, 2015.
PubMed
15) Vincent A, et al : Autoantibodies associated with dis eases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
 
P.124 掲載の参考文献
1) Nakazawa H, et al : Screening tests using serum tissue transglutaminase IgA may facilitate the identification of undiagnosed celiac disease among Japanese population. Int J Med Sci 11 : 819-823, 2014.
PubMed
2) Ihara M, et al : Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med 45 : 135-140, 2006.
PubMed
3) Hadjivassiliou M, et al : Cerebellar ataxia as a possible organ-specific autoimmune disease. Mov Disord 23 : 1370-1377, 2008.
PubMed
4) 田中伸幸ほか : 脊髄小脳変性症の画像診断におけるvoxel-based morphometryの有用性. BRAIN and NERVE : 神経研究の進歩 66 : 699-704, 2014.
 
5) Mitoma H, et al : Consensus Paper : Neuroimmune Mechanisms of Cerebellar Ataxias. Cerebellum 2015. [Epub ahead of print]
 
6) Hadjivassiliou M, et al : Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 74 : 1221-1224, 2003.
PubMed
7) Burk K et al : Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Ann Neurol 50 : 827-828. 2001.
PubMed
8) Sander HW, et al : Cerebellar ataxia and coeliac disease. Lancet 362 : 1548, 2003.
PubMed
9) Souayah N, et al : Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol 15 : 1300-1303, 2008.
PubMed
10) 水澤英洋ほか : 小脳失調患者における抗グリアジン抗体測定の意義. 免疫性神経疾患に関する調査研究班研究報告書, 2012.
 
11) Manto MU, et al : Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis 6 : 3, 2011.
PubMed
12) Ishida K, et al : Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase-associated cerebellar ataxia. J Neurol Neurosurg Psychiatry 78 : 190-192, 2007.
 
13) Nnnri K et al : Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum 12 : 171-175, 2013.
 
14) Takino T, et al : Case of subacute cerebellar ataxia with anti-glutamic acid decarboxylase antibodies in cerebrospinal fluid, but not in serum. Neurology and Clinical Neuroscience 3 (1) : 44-45, 2015.
 
15) 米田誠 : 橋本脳症-小脳失調型を中心に-. 臨床神経 52 : 1369-1371, 2012.
 
P.129 掲載の参考文献
1) Koga M, et al : Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis : epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 83 : 1210-1215, 2012.
PubMed
2) Saito T, et al : Nationwide survey of Guillain-Barre syndrome in Japan : therapeutic preliminary report. Prog Med 19 : 2369-2374, 1999.
 
3) Mitsui Y, et al : A multicentre prospective study of Guillain-Barre syndrome in Japan : a focus on the incidence of subtypes. J Neurol Neurosurg Psychiatry 86 : 110-114, 2015.
PubMed
4) Ito M, et al : Bickerstaff s brainstem encephalitis and Fisher syndrome form a continuous spectrum : clinical analysis of 581 cases. J Neurol 255 : 674-682, 2008.
 
5) Chiba A, et al : Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31 : 677-679, 1992.
PubMed
6) Yuki N, et al : Molecular mimicry between GQIb ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 36 : 791-793, 1994.
 
7) Chiba A, et al : Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
PubMed
8) Plomp JJ, et al : Miller Fisher anti-GQ1b antibodies : alpha-latrotoxin-like effects on motor end plates. Ann Neurol 45 : 189-199, 1999.
 
9) Halstead SK, et al : Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in amurine model. Brain 131 : 1197-1208, 2008.
 
10) Saito K, et al : Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes : an in vitro study. J Neurol Neurosurg Psychiatry 84 : 756-765, 2013.
 
11) Fox RJ, et al : Treatment of Bickerstaff s brainstem encephalitis with immune globulin. J Neurol Sci 178 : 88-90, 2000.
 
12) Odaka M, et al : Bickerstaff's brainstem encephalitis : clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 126 : 2279-2290, 2003.
 
13) van Doorn PA, et al : IVIG treatment and prognosis in Guillain-Barre syndrome. J Clin Immunol 30 : 74-78, 2010,
 
P.133 掲載の参考文献
1) Pang KK et al : A prospective study of the presentation and management dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Pediatr Neurol 14 : 156-161, 2010.
 
2) Tate ED, et al : Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nursing 22 : 8-9, 2005.
 
3) Ko MW, et al : Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 28 : 58-68, 2008.
PubMed
4) Bataller L, et al : Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 124 : 437-443, 2001.
PubMed
5) Klaas JP, et al : Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 69 : 1598-1607, 2012.
PubMed
6) Digre KB : Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 43 : 1165-1175, 1986.
PubMed
7) Russo C, et al : Long-term neurological outcome in children with opsoclonus-myoclonus associated with neuroblastoma : a report from the pediatric oncology group. Med Pediatr Oncol 28 : 284-288, 1997.
 
8) Korfei M, et al : Functional characterization of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol 170 : 150-157, 2005.
 
9) Wong AM, et al : Opsoclonus in three dimensions : oculographic, neuropathologic and modeling correlates. J Neurol Sci 189 : 71-81, 2001.
 
10) Luque FA, et al : Anti-Ri : an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 29 : 241-251, 1991.
PubMed
11) Laroumagne S, et al : "Dancing eye syndrome" secondary to opsoclonus-myoclonus syndrome in small-cell lung cancer. Case Rep Med 2014 : 545490, 2014.
PubMed
12) Rossor AM, et al : Opsoclonus-myoclonus syndrome due to squamous cell carcinoma of the oesophagus. BMJ Case Rep 2014 Mar 3 ; 2014. pii : bcr2013202849. doi : 10.1136/bcr-2013-202849.
 
13) Kidher ES, et al : An interesting collection of paraneoplastic syndromes in a patient with a malignant thymoma. BMJ Case Rep 2012 Jul 3 ; 2012. pii : bcrO220125790. doi : 10.1136/bcr.02.2012. 5790.
 
14) Titulaer MJ, et al : Screening for tumours in paraneoplastic syndromes : report of an EFNS Task Force. Eur J Neurol 18 : 19-27, 2011.
 
15) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
16) Pranzatelli MR, et al : Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28 : 585-593, 2006.
PubMed
17) Pranzatelli MR, et al : Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer 58 : 988-991, 2012.
PubMed
18) Ketterl TG, et al : Ofatumumab for refractory opsoclonus-myoclonus syndrome following treatment of neuroblastoma. Pediatr Blood Cancer 60 : E163-165, 2013.
PubMed
P.137 掲載の参考文献
1) Giometto B, et al : Sub-acute cerebellar degeneration with anti-Yo autoantibodies : immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol 23 : 468-474, 1997.
PubMed
2) Voltz R, et al : T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 51 : 1146-1150, 1998.
PubMed
3) Albert ML, et al : Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4 : 1321-1324, 1998.
PubMed
4) Tanaka M, et al : Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 168 : 28-31, 1999.
PubMed
5) Tanaka M, et al : Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration. J Neurol Sci 188 : 61-65, 2001.
PubMed
6) Tanaka M, et al : Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 201 : 9-12, 2002.
PubMed
7) Tani T, et al : Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 196 : 166-169, 2008.
PubMed
8) Tanaka M, et al : Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 97 : 96-101, 1995.
PubMed
9) Sillevis Smitt P, et al : Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342 : 21-27, 2000.
PubMed
10) Probst C, et al : Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2 : e68, 2015.
PubMed
11) Marignier R, et al : Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis : a primary autoimmune disease? Arch Neurol 67 : 627-630, 2010.
PubMed
12) Hoftberger R, et al : Patient with Homer-3 antibodies and cerebellitis. JAMA Neurol 70 : 506-509, 2013.
PubMed
P.142 掲載の参考文献
1) Sioka C, et al : Paraneoplastic immune-mediated neurological effects of systemic cancers. Expert Rev Clin Immunol 10 : 621-630, 2014.
PubMed
2) Tanaka M, et al : Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 201 : 9-12, 2002.
PubMed
3) Zaborowski MP, Michalak S : Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin Dev Immunol 2013 : 630602, 2013.
PubMed
4) Pittock SJ, Lennon VA : Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 65 : 629-632, 2008.
 
5) Collongues N, et al : Neuromyelitis optica in France. A multicenter study of 125 patients. Neurology 74 : 736-742, 2010.
 
6) Quek AM, et al : Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol 69 : 1039-1043, 2012.
PubMed
7) Frasquet M, et al : Longitudinally extensive transverse myelitis with AQP4 antibodies reviealing ovarian teratoma. J Neuroimmunol 263 : 145-147, 2013.
PubMed
8) Figeora M, et al : Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4. JAMA Neurol 71 : 495-498, 2014.
 
9) Flanagan EP, et al : Paraneoplastic isolated myelopathy : clinical course and neuroimaging clues. Neurology 76 : 2089-2095, 2011.
PubMed
10) Mas N, et al : Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 82 : 1399-1401, 2011.
PubMed
11) Balint B, et al : Progressive encephalomyelitis with rigidity and myoclonus : anew variant with DPPX antibodies. Neurology 82 : 1521-1528, 2014.
 
12) Carvajal-Gonzalez A, et al : Glycine receptor antibodies in PERM and related syndromes : characteristics, clinical features and outcomes. Brain 137 : 2178-2192, 2014.
PubMed
13) Martinez-Hernandez E, et al : Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 72 : 187-193, 2015.
 
14) Irani SR, et al : Cell-surface central nervous system autoantibodies : clinical relevance and emerging paradigms. Ann Neurol 76 : 168-184, 2014.
PubMed
15) Lancaster E, et al : Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 77 : 1698-1701, 2011.
PubMed
16) Pittock AJ, et al : Amphiphysin autoimmunity ; Paraneoplastic accompaniments. Ann Neurol 58 : 96-107, 2005.
 
P.146 掲載の参考文献
1) Voltz R : Paraneoplastic neurological syndromes : an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1 : 294-305, 2002.
 
2) Gultekin SH, et al : Paraneoplastic limbic encephalitis : neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 : 1481-1494, 2000.
PubMed
3) Levpoldt F, et al : Paraneoplastic neurological syndromes. Clin Exp Immunol 175 : 336-348, 2014.
 
4) Tanaka M, et al : Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 168 : 28-31, 1999.
PubMed
5) Albert ML et al : Detection and treatment of activated T cells in the cerebrospinal nuid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 47 : 9-17, 2000.
 
6) Dalmau J, et al : Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 7 : 1091-1098, 2008,
PubMed
7) Irani SR, et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
8) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
9) Szabo A, et al : HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 67 : 325-333, 1991.
PubMed
10) Honnorat J, et al : Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80 (4) : 412-416, 2009.
PubMed
11) Dalmau J, et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 : 1831-1844, 2004.
PubMed
12) Pittock SJ, et al : Amphiphysin autoimmunity : paraneoplastic accompaniments. Ann Neurol 58 : 96-107, 2005.
PubMed
13) Rosenfeld MR, Dalmau J : Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol 14 (4) : 528-538, 2013.
PubMed
14) Melzer N, et al : Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 260 : 1215-1233, 2013.
PubMed
P.152 掲載の参考文献
1) Blaes F : Paraneoplastic brain stem encephalitis. Curr Treat Options Neurol 15 : 201-209, 2013.
PubMed
2) Graus F, Dalmau J : Paraneoplastic neurological syndromes. Curr Opin Neurol 25 : 795-801, 2012.
PubMed
3) Posner JB : Paraneoplastic syndromes involving the nervous system. In : Aminoff's Neurology and General Medicine, 5th ed (ed by Aminoff MJ, Josephson SA), p563-590, Academic Press, London, 2014.
 
4) Saiz A, et al : Anti-Hu-associated brainstem encephalitis. J Neurol Neurosurg Psychiatry 80 : 404-407, 2009.
PubMed
5) Sutton IJ, et al : Paraneoplastic brainstem encephalitis and anti-Ri antibodies. J Neurol 249 : 1597-1598, 2002.
PubMed
6) Pittock SJ, et al : Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol 67 : 1109-1115, 2010.
PubMed
7) Dalmau J, et al : Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 : 1831-1844, 2004.
PubMed
8) Panzer J, Dalmau J : Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol 24 : 346-353, 2011.
PubMed
9) Dalmau J, et al : Anti-NMDA-receptor encephalitis : case series and analysis of the effects of antibodies. Lancet Neurol 7 : 1091-1098, 2008.
PubMed
10) Takahashi Y : Epitope of autoantibodies to N-methyl-D-aspartate receptor heteromers in paraneoplastic limbic encephalitis. Ann Neurol 64 : 110-111, 2008 ; and author reply 111-112.
 
11) Armangue T, et al : A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 75 : 435-441, 2014.
PubMed
12) Mundiyanapurath S, et al : GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol 259 : 88-91, 2013.
PubMed
13) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
14) Jubelt B, et al : Rhombencephalitis/brainstem encephalitis. Curr Neurol Neurosci Rep 11 : 543- 552, 2011.
 
15) Viaccoz A, Honnorat J : Paraneoplastic neurological syndromes : general treatment overview. Curr Treat Options Neurol 15 : 150-168, 2013.
PubMed
P.156 掲載の参考文献
1) Adamus G : Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2 : 63-68, 2003.
PubMed
2) Dropcho EJ : Neurologic paraneoplastic syndromes. J Neurol Sci 153 : 264-278, 1998.
PubMed
3) Dhingra A, et al : Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. J Neurosci 31 : 3962-3967, 2011.
 
4) Kondo M, et al : Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. PLoS One 6 : e19911, 2011.
PubMed
5) Morita Y, et al : Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy. Jpn J Ophthalmol 58 : 166-171, 2014.
 
6) Koch KW : Biochemical mechanism of light adaptation in vertebrate photoreceptors. Trends Biochem Sci 17 : 307-311, 1992.
PubMed
7) Polans AS, et al : Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 92 : 9176-9180, 1995.
PubMed
8) Ohguro H, et al : Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40 : 3160-3167, 1999.
PubMed
9) Ohguro H, et al : Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 137 : 1117-1119, 2004.
PubMed
10) Dalal MD, et al : Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM 1) autoantibody testing : a novel approach. Ophthalmology 120 : 2560-2564, 2013.
PubMed
11) Koike C, et al : TRPM1 is a component of the retinal ON bipolar cell transduction channel in the mGluR6 cascade. Proc Natl Acad Sci USA 107 : 332-337, 2010.
PubMed
12) Nakamura M, et al : TRPM1 mutations are associated with the complete form of congenital stationary night blindness. Mol Vis 16 : 425-437, 2010.
PubMed
13) Guy J, Aptsiauri N : Treatment of paraneoplastic visual loss with intravenous immunoglobulin : report of 3 cases. Arch Ophthalmol 117 : 471-477, 1999.
PubMed
14) Subhadra C, et al : Improvement in Visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 28 : 23-26, 2008.
 
15) Monzon JG, et al : Retinopathy associated with adjuvant high-dose interferon-alpha2 b in a patient with resected melanoma : a case report and review of the literature. Oncologist 17 : 384-387, 2012.
 
P.161 掲載の参考文献
1) 大塚貴 : 傍腫瘍性神経筋疾患とは-定義と歴史. BRAIN and NERVE 神経研究の進歩 62 : 301-308, 2010.
 
2) Graus F, et al : Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 : 1135-1140, 2004.
PubMed
3) Giometto B, et al : Paraneoplastic neurologic syndrome in the PNS Euronetwork database : a European study from 20 centers. Arch Neurol 67 : 330-335, 2010.
PubMed
4) Vedeler CA, et al : Management of paraneoplastic neurological syndromes : report of an EFNS Task Force. Eur J Neurol 13 : 682-690, 2006.
PubMed
5) Volts R : Paraneoplastic neurological syndromes : an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1 : 294-305, 2002.
 
6) Koike H, et al : Paraneoplastic neuropathy : wide-ranging clinicopathological manifestations. Curr Opin Neurol 24 : 504-510, 2011.
PubMed
7) Oki Y, et al : Ataxic vs painfuI form of paraneoplastic neuropathy. Neurology 69 : 564-572, 2007.
PubMed
8) Keime-Guibert F, et al : Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68 : 479-482, 2000.
PubMed
9) Vernino S, et al : Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 6 : 55-62, 2004.
PubMed
P.165 掲載の参考文献
1) 松原四郎 : 悪性腫瘍を伴う多発筋炎と皮膚筋炎. 別冊日本臨牀 骨格筋症候群 (上巻), p291-295, 日本臨牀社, 2001.
 
2) Antiochos BB, et al : Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 36 : 2704-2710, 2009.
 
3) Sigurgeirsson B, et al : Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326 : 363-367, 1992.
 
4) Buchbinder R, et al : Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134 : 1087-1095, 2001.
PubMed
5) Huang YL, et al : Malignancies associated with dermatomyositis and polymyositis in Taiwan : a nationwide population-based study. Br J Dermatol 161 : 854-860, 2009.
PubMed
6) Peng JC, et al : Nasopharyngeal carcinoma with dermatomyositis. Analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121 : 1298-1301, 1995.
PubMed
7) Gerami P, et al : A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 157 : 637-644, 2007.
PubMed
8) Neri R et al : Cancer-associated myositis : a 35-year retrospective study of a monocentric cohort. Rheumatol Int 34 : 565-569, 2014.
PubMed
9) Sampson JB, et al : Paraneoplastic myopathy : response to intravenous immunoglobulin. Neuromuscul Disord 17 : 404-408, 2007.
PubMed
10) Bohan A, Peter JB : Polymyositis and dermatomyositis (in two parts). N Engl J Med 292 : 344-347, 403-407, 1975.
 
11) Dalakas MC, Hohlfeld R : Polymyositis and dermatomyositis. Lancet 362 : 971-982, 2003.
PubMed
12) Azuma Y, et al : Polymyositis with atypical pathological features associated with thymic carcinoma. Intern Med 48 : 163-168, 2009.
PubMed
13) Casciola-Rosen L, et al : Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201 : 591-601, 2005.
PubMed
14) Andras C, et al : Dermatomyositis and polymyositis associated with malignancy : a 21-year retrospective study. J Rheumatol 35 : 438-444, 2008.
PubMed
15) Hill CL, et al : Frequency of specific cancer types in dermatomyositis and polymyositis : a population-based study. Lancet 357 : 96-100, 2001.
PubMed
16) Zahr ZA, Baer AN : Malignancy in myositis. Curr Rheumatol Rep 13 : 208-215, 2011.
PubMed
17) Uchino M, et al : Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg 115 : 603-606, 2013.
PubMed
18) Chinoy H, et al : The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66 : 1345-1349, 2007.
PubMed
19) Oddis CV, et al : Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum 40 : S139, 1997.
 
20) Targoff IN, et al : Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 56 : S787, 2007.
 
21) Ichimura Y. et al : Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies : possible association with malignancy. Ann Rheum Dis 71 : 710-713, 2012.
PubMed
22) Kaji K et al : Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis : an association with malignancy. Rheumatology (Oxford) 46 : 25-28, 2007.
PubMed
23) Targoff IN, et al : A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54 : 3682-3689, 2006.
PubMed
24) Sato S, et al : Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52 : 1571-1576, 2005.
PubMed
25) Targoff IN, et al : Autoantibodies to transcriptional intermediary factor-1 gamma (TIF1-γ) in dermatomyositis. Arthritis Rheum 54 : S518, 2006.
 
26) Fujimoto M, et al : Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64 : 513-522, 2012.
PubMed
27) Trallero-Araguas E, et al : Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis : asystematic review and meta-analysis. Arthritis Rheum 64 : 523-532, 2012.
 
28) Mahmood S, Rodriguez Martinez de, Llano S : 18F-FDG PET detection of unknown primary malignancy in dermatomyositis. Clin Nucl Med 37 : e204-e205, 2012.
PubMed
P.171 掲載の参考文献
2) Titulaer MJ, et al : Lambert-Eaton myasthenic syndrome : from clinical characteristics to therapeutic strategies. Lancet Neurol 10 : 1098-1107, 2011.
PubMed
3) Nakao YK, et al : Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology 59 : 1773-1775, 2002.
PubMed
4) Takamori M, et al : Antibodies to synthetic peptides of the alphalA subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48 : 1261-1265, 1997.
 
5) Huijbers MG, et al : Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. Hum Immunol 74 : 849-851, 2013.
PubMed
6) O'Neill JH, et al : The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 : 577-596, 1988.
 
7) Odabashi Z, et al : Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome. Neurology 59 : 1085-1087, 2002.
 
8) Lorenzoni PJ, et al : Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome. J Neurol Sci 270 : 194-196, 2008.
PubMed
9) Graus F, et al : P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 : 764-766, 2002.
PubMed
10) Fukuda T, et al : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 53 : 21-28, 2003.
PubMed
11) Lennon VA, et al : Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 : 1467-1474, 1995.
PubMed
12) Wirtz PW : The Lambert-Eaton Myasthenic Syndrome : Clinical, Epidemiological and Immunological Studies, p 48-49, Febodruk B. V., Netherlands, 2005.
 
13) Titulaer MJ, et al : Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 29 : 902-908, 2011.
PubMed
14) Evoli A, et al : Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management. Neurol Sci 35 : 515-520, 2014.
PubMed
15) Tarr TB, et al : Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci 33 : 10559-10567, 2013.
PubMed
本村政勝, 福田卓 : Lambert-Eaton筋無力症候群. BRAIN and NERVE 63 : 745-754, 2011.
 
P.176 掲載の参考文献
1) Arimura K et al : Isaacs's yndrome as a potassium channelopathy of the nerve. Muscle Nerve Suppl 11 : S55-58, 2002.
 
2) Hart IK, et al : Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 : 1887-1895, 2002.
PubMed
3) Newsom-Davis J, Mills KR : Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 : 453-469, 1993.
PubMed
4) Arimura K et al : The origin of spontaneous discharges in acquired neuromyotonia. A Macro EMG study. Clin Neurophysiol 116 : 1835-1839, 2005.
PubMed
5) Sinha S, et al : Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 : 75-77, 1991.
PubMed
6) 有村公良, 渡邊修 : 免疫介在性ニューロミオトニア (Isaacs症候群). BRAIN and NERVE 62 : 401-410, 2010.
 
7) Klein CJ, et al : Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70 : 229-234, 2013.
PubMed
8) Liguori R, et al : Morvan's syndrome : clinical and serological observation in 29 cases. Brain 124 : 2417-2426, 2001.
 
9) Vincent A, et al : Potassium channel antibody-associated encephalopathy : apotentially immunotherapy-responsive form of limbic encephalitis. Brain 127 : 701-712, 2004.
 
10) 渡邊修 : VGKC関連抗体. BRAIN and NERVE 65 : 401-411, 2013.
 
11) Irani SR, et al : Antibodies to kv1 potassium channel complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
12) Nagado T, et al : Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122 : 2057-2066, 1999.
PubMed
13) 渡邊修ほか : 目でみるバイオサイエンス : Kチャネル異常 (Isaacs症候群). 内科 89 : 156-159, 2002.
 
14) Ahmed A, Simmons Z : Isaacs syndrome : A review. Muscle Nerve 52 (1)
PubMed
15) Tan KM, et al : Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70 : 1883-1890, 2008.
PubMed
P.180 掲載の参考文献
1) Walusinski O, Honnorat J : Augustin Morvan (1819-1897), a little-known rural physician and neurologist. Rev Neurol (Paris) 169 : 2-8, 2013.
PubMed
2) Liguori R, et al : Morvan's syndrome : peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 : 2417-2426, 2001.
 
3) Irani SR, et al : Morvan syndrome : clinical and serological observations in 29 cases. Ann Neurol 72 : 241-255, 2012.
PubMed
4) Irani SR et al : Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133 : 2734-2748, 2010.
 
5) 渡邊修 : VGKC関連抗体. BRAIN and NERVE 65 : 401-411, 2013.
 
6) Vincent A, et al : Autoantibodies associated with diseases of the CNS : new developments and future challenges. Lancet Neurol 10 : 759-772, 2011.
PubMed
7) Poliak S, et al : Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K+ channels. Neuron 24 : 1037-1047, 1999.
 
8) Lancaster E, et al : Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69 : 303-311, 2011.
PubMed
9) Sharma S, Sharma P : Morvan syndrome : after scrotal sac drainage and chemical instillation in hydrocele. Neurol India 61 : 300-302, 2013.
PubMed
10) Vincent A, Irani SR : Caspr2 antibodies in thymoma. J Thorac Oncol 50 : 5277-5280, 2010.
 
11) Klein CJ, et al : Insights from LGI1 and Caspr2 potassium channel complex autoantibody subtyping. JAMA Neurol 70 : 229-234, 2013,
PubMed
12) Sekiguchi Y, et al : Potassium channel antibody-associated encephalitis with hypothalamic lesions and intestinal pseudo-obstruction. J Neurol Sci 269 : 176-179, 2008.
PubMed
13) Takahashi H, et al : Development of Isaacs' syndrome following complete recovery of voltage-gated potassium channel antibody-associated limbic encephalitis. J Neurol Sci 275 : 185-187, 2008.
PubMed
14) El-Bitar MK, et al : Morvan syndrome following B-cell lymphoma. J Child Neurol 25 : 1038-1041, 2010.
PubMed
15) Ong E, et al : Dramatic improvement after rituximab in a patient with paraneoplastic treatmentrefractory Morvan syndrome associated with anti-CASPR2 antibodies. Eur J Neurol 20 : e96-97, 2013.
 
P.187 掲載の参考文献
1) Moersch FP, Woltman HW : Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome) ; report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 31 : 421-427, 1956.
PubMed
2) Gordon EE, et al : A critical survey of stiff-man syndrome. Am J Med 42 : 582-599, 1967.
PubMed
3) Solimena M, et al : Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318 : 1012-1020, 1988.
 
4) McKeon A, et al : Stiff-man syndrome and variants : clinical course, treatments, and outcomes. Arch Neurol 69 : 230-238, 2012.
PubMed
5) 石井亜紀子 : Stiff-person症候群とその他の脊髄症. 脳神経 62 : 377-385, 2010.
 
6) Barker RA, et al : Review of 23 patients affected by the stiff man syndrome : clinical subdivision into stiff trunk (man) syndrome. stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 65 : 633-640, 1998.
PubMed
7) Brown P, et al : The stiff leg syndrome. J Neurol Neurosurg Psychiatry 62 : 31-37, 1997.
PubMed
8) 松本兵之, 宇川義一 : Stiff-person症候群. Brain Medical 20 : 283-289, 2008.
 
9) Ishizawa K, et al : Large motor neuron involvement in Stiff-man syndrome : aqualitative and quantitative study. Acta Neuropathol 97 : 63-70, 1999.
 
10) Solimena M, De Camilli P : Autoimmunity to glutamic acid decarboxylase (GAD) in Stiff-Man syndrome and insulin-dependent diabetes mellitus. Trends Neurosci 14 : 452-457, 1991.
PubMed
11) Meinck HM, Thompson PD : Stiff man syndrome and related conditions. Mov Disord 17 : 853-866, 2002.
PubMed
12) Raju R, et al : Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 175 : 7755-7762, 2005.
PubMed
13) Saiz A, et al : Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies : diagnostic clues for this association. Brain 131 : 2553-2563, 2008.
PubMed
14) De Camilli P, et al : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178 : 2219-2223, 1993.
PubMed
15) Sommer C, et al : Paraneoplastic stiff-person syndrome : passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 365 : 1406-1411, 2005.
PubMed
16) Butler MH, et al : Autoimmunity to gephyrin in Stiff-Man syndrome. Neuron 26 : 307-312, 2000.
PubMed
17) Hutchinson M, et al : Progressive encephalomyelitis, rigidity, and myoclonus : a novel glycine receptor antibody. Neurology 71 : 1291-1292, 2008.
PubMed
18) Carvajal-Gonzalez A, et al : Glycine receptor antibodies in PERM and related syndromes : characteristics, clinical features and outcomes. Brain 137 : 2178-2192, 2014.
PubMed
19) McKeon A, et al : Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 70 : 44-50, 2013.
PubMed
20) McCabe DJ, et al : Paraneoplastic "stiff person syndrome" with metastatic adenocarcinoma and anti-Ri antibodies. Neurology 6211402-1404, 2004.
PubMed
21) Boronat A, et al : GABA (B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders, Neurology 76 : 795-800, 2011.
PubMed
22) Dalakas MC, et al : Stiff person syndrome : quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57 : 780-784, 2001.
PubMed
23) Levy LM, et al : Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62 : 970-974, 2005.
PubMed
24) Perani D, et al : PET evidence of central GABAergic changes in stiff-person syndrome. Mov Disord 22 : 1030-1033, 2007.
PubMed
25) Duddy ME, Baker MR : Stiff person syndrome. Front Neurol Neurosci 26 : 147-165, 2009.
PubMed
26) Koerner C, et al : Stiff-person syndromes : motor cortex hyperexcitability correlates with anti-GAD autoimmunity. Neurology 62 : 1357-1362, 2004.
PubMed
27) Nakane S, et al : Successful treatment of stiff person syndrome with sequential use of tacrolimus. J Neurol Neurosurg Psychiatry 84 : 1177-1180, 2013.
PubMed
28) Lorish TR, et al : Stiff-man syndrome updated. Mayo Clin Proc 64 : 629-636, 1989.
PubMed
29) Dalakas MC : Advances in the pathogenesis and treatment of patients With stiff person syndrome. Curr Neurol Neurosci Rep 8 : 48-55, 2008.
PubMed
30) Dalakas MC : Stiff person syndrome : advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11 : 102-110, 2009.
PubMed
31) Espay AJ, Chen R : Rigidity and spasms from autoimmune encephalomyelopathies : stiff-person syndrome. Muscle Nerve 34 : 677-690, 2006.
PubMed
32) Dalakas MC, et al : High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345 : 1870-1876, 2001.
PubMed
33) Penn RD, Mangieri EA : Stiff-man syndrome treated with intrathecal baclofen. Neurology 43 : 2412, 1993.
PubMed
34) Hao W, et al : Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes : a 2-year study. J Neurol 246 : 731-735, 1999.
PubMed
35) Harding AE, et al : Plasma exchange and immunosuppression in the stiff man syndrome. Lancet 2 : 915, 1989.
PubMed
36) Meinck HM : Stiff man syndrome. CNS Drugs 15 : 515-526, 2001.
PubMed
37) Squintani G, et al : Efficacy of pregabalin in a case of stiff-person syndrome : clinical and neurophysiological evidence. J Neurol Sci 314 : 166-168, 2012.
 
38) Ruegg SJ, et al : Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology 62 : 338, 2004.
 
39) Baker MR, et al : Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 76 : 999-1001, 2005.
PubMed
P.191 掲載の参考文献
1) Yonekawa T, et al : A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry 85 : 732-739, 2014.
PubMed
2) Yokoseki A, et al : Hypertrophic pachymeningitis : significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137 : 520-536, 2014.
PubMed
3) Nozaki I, et al : Prospective 10-year surveillance of human prion diseases in Japan. Brain 133 : 3043-3057, 2010.
PubMed
4) Starosta MA, Brandwein SR : Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology 68 : 1079-1080, 2007.
PubMed
5) Ii Y, Kuzuhara S : Rheumatoid cranial pachymeningitis successfully treated with long-term corticosteroid. Rheumatol Int 29 : 583-585, 2009.
PubMed
6) Ahmadi-Simab K et al : Pachymeningitis in mixed connective tissue disease. Ann Rheum Dis 64 : 1656-1657, 2005.
PubMed
7) Ranoux D, et al : Meningeal sarcoidosis, pseudo-meningioma, and pachymeningitis of the convexity. J Neurol Neurosurg Psychiatry 55 : 300-303, 1992.
PubMed
8) Li JY, et al : Hypertrophic cranial pachymeningitis and lymphocytic hypophysitis in Sjogren's syndrome. Neurology 52 : 420-423, 1999.
 
9) Callebaut J, et al : Contrast-enhanced MR imaging of tuberculous pachymeningitis cranialis hypertrophica : case report. AJNR Am J Neuroradiol 11 : 821-822, 1990.
PubMed
10) Thurtell MJ, et al : Tuberculous cranial pachymeningitis. Neurology 68 : 298-300, 2007.
PubMed
11) Murai H, et al : Hypertrophic cranial pachymeningitis due to Aspergillus flavus. Clin Neurol Neurosurg 94 : 247-250, 1992.
PubMed
12) Nadgir DB, et al : Cavernous sinus syndrome due to syphilitic pachymeningitis. Neurol India 51 : 289-290, 2003.
PubMed
13) Kawano Y, Kira J : Chronic hypertrophic cranial pachymeningitis associated with HTLV-I infection. J Neurol Neurosurg Psychiatry 59 : 435-437, 1995.
PubMed
P.197 掲載の参考文献
1) Tolosa E : Periarteritic lesions of the carotid siphon with the clinical features of a carotid infraclinoidal aneurysm. J Neurol Neurosurg Psychiatry 17 : 300-302, 1954.
PubMed
2) Hunt WE, et al : Painful ophthalmoplegia. Its relation to indolent inflammation of the carvernous sinus. Neurology 11 : 56-62, 1961.
PubMed
3) Smith JL, Taxdal DS : Painful ophthalmoplegia. The Tolosa-Hunt syndrome. Am J Ophthalmol 61 : 1466-1472, 1966.
PubMed
4) Hunt WE : Tolosa-Hunt syndrome : one cause of painful ophthalmoplegia. J Neurosurg 44 : 544-549, 1976.
PubMed
5) 後藤文男ほか : Tolosa-Hunt症候群の全国*集計 (第1報). 厚生省特定疾患「ウイリス動脈輪閉塞症に関する」研究班, 昭和56年度研究報告書, p51-59, 1981.
 
6) Hunt WE, Brightman RP : The Tolosa-Hunt syndrome : a problem in differential diagnosis. Acta Neurochir Suppl (Wien) 42 : 248-252, 1988.
PubMed
7) Headache Classification Committee of the International Headache Society (IHS) : The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33 : 629-808, 2013.
PubMed
8) 国際頭痛学会・頭痛分類委員会 : 13.7トロサ・ハント症候群. 国際頭痛分類 第3版 beta版 (日本頭痛学会・国際分類委員会訳), p162, 医学書院, 2014.
 
9) Itokawa K, et al : Dural arteriovenous fistula as a possible cause of Tolosa-Hunt syndrome : a case report. J Neurol 257 : 846-847, 2010.
PubMed
10) Colnaghi S, et al : ICHD-II diagnostic criteria for Tolosa-Hunt syndrome in idiopathic inflammatory syndromes of the orbit and/or the cavernous sinus. Cephalalgia 28 : 577-584, 2008.
PubMed
11) Zhang W, et al : Factors that influence Tolosa-Hunt syndrome and the short-term response to steroid pulse treatment. J Neurol Sci 341 : 13-16, 2014.
PubMed
P.202 掲載の参考文献
1) バセドウ病診断ガイドライン 2010, 日本甲状腺学会. [http://www.japanthyroid.jp/doctor/guideline/japanese.html]
 
2) 甲状腺クリーゼの診断基準 (第2版), 日本甲状腺学会. [http://www.japanthyroid.jp/doctor/img/crisis2.pdf]
 
3) Akamizu T, et al : Diagnostic criteria and clinico-epidemiological features of thyroid storm based on a nationwide survey. Thyroid 22 : 661-679, 2012.
 
4) バセドウ病治療ガイドライン 2011 (日本甲状腺学会編), 南江堂, 2011.
 
5) バセドウ病悪性眼球突出症 (甲状腺眼症) の診断基準と治療指針 (第1次案), 日本甲状腺学会. [http://www.japanthyroid.jp/doctor/img/basedou.pdf]
 
P.208 掲載の参考文献
1) 赤水尚史 : 橋本病の発症機序. よくわかる甲状腺疾患のすべて (改訂第2版) (伴良雄編), p356-362, 永井書店, 2009.
 
P.212 掲載の参考文献
1) Smith BR, Hall R : Thyroid-stimulating immunoglobulins in Graves disease. Lancet 2 : 427-431, 1974.
PubMed
2) Endo K, et al : Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 46 : 734-739, 1978.
 
3) Matsuura N, et al : Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. N Engl J Med 303 : 738-741, 1980.
PubMed
4) Matsuura N, Konishi J : Transient hypothyroidism in infants born to mothers with chronic thyroiditis-a nationwide study of twenty-three cases. The Transient Hypothyroidism Study Group. Endocrinol Jpn 37 : 369-379, 1990.
 
5) Konishi J, et al : Primary myxedema with thyrotropin-binding inhibitor immunoglobulins. Clinical and laboratory observation in 15 patients. Ann Intern Med 103 : 26-31, 1985.
 
6) Matsuura M, et al : Comparison of atrophic and goitrous auto-immune thyroiditis in children : clinical, laboratory and TSH-receptor antibody studies. Eur J Pediatr 149 : 529-533, 1990.
 
7) Parks JS, et al : The impact of transient hypothyroidism on the increasing rate of congenital hypothyroidism in the United States. Pediatrics 125 (Suppl 2) : s54-s63, 2010.
PubMed
8) Matsuura N, et al : The prediction of thyroid function in infants born to mothers with chronic thyroiditis. Endocrinol Jpn 36 : 865-871, 1989.
PubMed
9) Sutherland LM, et al : Familial nongoitrous cretinism apparently due to maternal antithyroid antibody. N Engl J Med 263 : 336, 1960.
 
10) 松浦信夫 : TSH受容体阻害抗体によるによる新生児一過性, 家族性甲状腺機能低下症の病態解明. 小児内科 41 : 1365-1372, 2009.
 
11) 松浦信夫 : 甲状腺機能の母児相関. 日未熟児新生児会誌 6 : 43-47, 1994.
 
12) Ochi Y, et al : Conversion of TBAb response to TSAb response by anti-human IgG antibody. Endocr Metab Immune Disord Drug Targets 13 : 311-315, 2013.
PubMed
13) Amino N, et al : In-vitro conversion of blocking type anti-TSH receptor antibody to the stimulating type by anti-human IgG antibodies. Clin Endocrinol (Oxf) 27 : 615-624, 1987.
PubMed
P.219 掲載の参考文献
1) Papapetrou PD, Jackson IM : Thyrotoxicosis due to "silent" thyroiditis. Lancet 1 (7903) 361363, 1975.
PubMed
2) Gluck FB, et al : Chronic lymphocytic thyroiditis, thyrotoxicosis, and low radioactive iodine uptake. Report of four cases. N Engl J Med 293 : 624-628, 1975.
 
3) 小澤安則 : Silent thyroiditisの甲状腺基礎疾患について. ホルモンと臨床 34 (増刊) : 49-56, 1987.
 
4) 小澤安則 : バセドウ病の診断-破壊性甲状腺炎との鑑別. 内科 80 : 826-830, 1997.
 
5) 小澤安則 : 無痛性甲状腺炎の診断と治療. よくわかる甲状腺疾患のすべて (改訂第2版) (伴良雄編), p45-52, 永井書店, 2009.
 
6) 小澤安則 : 無痛性甲状腺炎, 亜急性甲状腺炎. 日本医師会雑誌 141 (11) : 2439-2444, 2013.
 
7) Amino N, et al : High prevalence of transient postpartum thyrotoxicosis and hypothyroidism. N Engl J Med 306 : 849-852, 1982.
 
8) 網野信行, 日高洋 : 出産後一過性甲状腺異常. 日本医師会雑誌 108 : 87-96, 1992.
 
9) Takasu N, et al : Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma. N Engl J Med 322 (24) : 1708-1712, 1990.
 
10) Orlov S, et al : Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab 100 : 1738-1741, 2015.
PubMed
11) Ota H, et al : Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 67 : 41-45, 2007.
PubMed
P.221 掲載の参考文献
1) Itoh M, et al : Tissue microcircumstances for leukocytic infiltration into the testis and epididymis in mice. J Reprod Immunol 67 : 57-67, 2005.
PubMed
2) Naito M, et al : Experimental autoimmune orchitis as a model of immunological male infertility. Med Mol Morphol 45 : 185-189, 2012.
PubMed
3) 平井宗一, 伊藤正裕 : 精巣病理学者 畠山茂の残した日本人剖検所見が示唆するもの. Reproductive Immunology and Biology 27 : 7-13, 2012.
 
4) Naito M, et al : Histopathology of the tubuli recti at the start of experimenta1 autoimmune orchitis in mice. Med Mol Morphol 42 : 230-235, 2009.
PubMed
5) Itoh M, et al : New experimental model for adoptive transfer of murine autoimmune orchitis. Andrologia 23 : 415-420, 1991.
PubMed
6) Naito M, et al : Post-infiammation stage of autoimmune orchitis induced by immunization with syngeneic testicular germ cells alone in mice. Med Mol Morphol 45 : 35-44, 2012.
 
7) 谷口久哲, 松田公志 : 男性不妊-乏精子症・無精子症, 性交障害 (不妊原因診断とARTの前の対処法). 臨床婦人科産科 65 : 1166-1169, 2011.
 
8) 宮川康ほか : 男性不妊症に対するマイクロサージェリー 顕微鏡下精巣内精子採取術. 臨床泌尿器科 62 : 575-580, 2002.
 
9) 宮川康ほか : 難治性不妊の非ART治療 造精機能障害. 産婦人科治療 85 : 543-546, 2002.
 
10) Fairley KF, et al : Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1 (7750) : 568-569, 1972.
PubMed
11) 岩崎雅志ほか : シクロスポリン, アザチオプリン, およびミゾリビンのラット造精機能へ及ぼす影響. 日泌会誌 87 : 42-49, 1996.
 
12) Caneguim BH, et al : Structural alterations in the seminiferous tubules of rats treated With immunosuppressor tacrolimus. Reprod Biol Endocrinol 25 : 19, 2009.
 
P.226 掲載の参考文献
1) La Marca A, et al : Primary ovarian insufficiency : autoimmune causes. Curr Opin Obstet Gynecol 22 : 277-282, 2010.
PubMed
2) Khole V : Does ovarian autoimmunity play a role in the pathophysiology of premature ovarian insufficiency? J Midlife Health 1 : 9-13, 2010.
PubMed
3) Sharara FI, et al : The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol 179 : 804-812, 1998.
PubMed
4) Practice Committee of the American Society for Reproductive Medicine : Testing and interpreting measures of ovarian reserve : a committee opinion. Fertil Steril 98 : 1407-1415, 2012.
PubMed
5) Kalantaridou SN, Nelson LM : Premature ovarian failure is not premature menopause. Ann NY Acad Sci 900 : 393-402, 2000.
 
6) Shelling AN : Premature ovarian failure. Reproduction 140 : 633-641, 2010.
PubMed
7) Conway GS : Premature ovarian failure. Br Med Bull 56 : 643-649, 2000.
PubMed
8) Jin M, et al : An update on primary ovarian insufficiency. Sci China Life Sci 55 : 677-686, 2012.
PubMed
9) Carp HJ, et al : The autoimmune bases of infertility and pregnancy loss. J Autoimmun 38 : 266-274, 2012.
 
10) Kawamura K, et al : Hippo signaling disnlption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA 110 : 17474-17479, 2013.
PubMed
11) 石塚文平 : 早発卵巣不全. 卵子学 (森崇英編), p 586-593, 京都大学学術出版会, 2011.
 
12) Silva CA, et al : Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 11 : 419-425, 2002.
 
13) Cabral de Sousa D, et al : Anti-corpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. Lupus 14 : 618-624, 2005.
 
14) Aikawa NE, et al : Menstrual and hormonal alterations in juvenile dermatomyositis. Clin Exp Rheumatol 28 : 571-575, 2010.
PubMed
15) Betterle C, Volpato M : Adrenal and ovarian autoimmunity. Eur J Endocrinol 138 : 16-25, 1998.
PubMed
16) Silva CA Brunner HI : Gonadal functioning and preservation of reproductive fitness with juvenile systemic erythematosus. Lupus 16 : 593-599, 2007.
PubMed
17) Pasoto SG, et al : Anti-corpus luteum antibody : a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 26 : 1087-1093, 1999.
PubMed
18) Euthymiopoulou K, et al : Antiovarian antibodies in primary Sjogren's syndrome. Rheumatol Int 27 : 1149-1155, 2007.
 
19) Takamizawa S, et al : Detection of antizona pellucida antibodies in the sera from premature ovarian failure patients by a highly speciflc test. Fertil Steril 88 : 925-932, 2007.
 
20) Haller-Kikkatalo K, et al : Review on autoimmune reactions in female infertility : antibodies to follicle stimulating hormone. Clin Dev Immunol 2012 : 762541, 2012,
PubMed
21) Dal Pra C, et al : Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison's disease. Eur J Endocrinol 148 : 565-570, 2003.
 
22) Goswami D, Conway GS : Premature ovarian failure. Hum Reprod Update 11 : 391-410, 2005.
PubMed
23) Altuntas CZ, et al : Autoimmune targeted disruption of the pituitary-ovarian a) ds causes premature ovarian failure. J Immunol 177 : 1988-1996, 2006.
 
24) Welt CK : Autoimmune oophoritis in the adolescent. Ann N Y Acad Sci 1135 : 118-122, 2008.
PubMed
25) Kalantaridou SN, et al : Treatment of autoimmune premature ovarian failure. Hum Reprod 14 : 1777-1782, 1999.
PubMed
26) Silva CA, et al : Autoimmune primary ovarian insufficiency. Autoimmun Rev 13 : 427-430, 2014.
PubMed
27) Cowchock FS, et al : Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome). Am J Obstet Gynecol 115 : 118-119, 1988.
 
28) Corenblum B, et al : High-dose, short-term glucocorticoids for the treatment of infertility resulting from premature ovarian failure. Fertil Steril 59 : 988-991, 1993.
PubMed
P.231 掲載の参考文献
1) 明比祐子ほか : 副腎皮質機能低下症. medicina 50 : 1823-1827, 2013.
 
2) Neufeld M, et al : Autoimmune polyglandular syndromes. Pediatr Ann 9 : 154-162, 1980.
PubMed
3) Betterle C, et al : Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes : autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 23 : 327-364, 2002.
PubMed
4) 後藤穣, 柳瀬敏彦 : 副腎領域における自己免疫疾患. ホルモンと臨床 56 : 159-168, 2008.
 
5) 柳瀬敏彦ほか : アジソン病, 副腎性サブクリニカルクッシング症候群の全国における実態調査厚生労働科学研究費補助全 (難治性疾患克服研究事業) 副腎ホルモン産生異常に関する調査研究班 平成20-22年度総合研究報告書. p139-146, 2011.
 
6) Sato K, et al : A novel missense mutation of AIRE gene in a patient with autoimmune polyendocrinopathy, candidiasis and ectodermal dystrophy (APECED), accompanied with progressive muscular atrophy : case report and review of the literature in Japan. Endocr J 49 : 625-633, 2002.
 
7) Betterle C, et al : Autoimmune polyglandular syndrome Type 2 : the tip of an iceberg? Clin Exp Immunol 137 : 225-233, 2004.
PubMed
8) Nomura K, et al : Addison's disease in Japan : characteristics and changes revealed in a nationwide survey. Intern Med 33 : 602-606, 1994.
 
9) Nagamine K, et al : Positional cloning of the APECED gene. Nat Genet 17 : 393-398, 1997.
PubMed
10) Kumar PG, et al : Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol Metab Clin North Am 31 : 321-338, 2002.
PubMed
11) Wolff AS, et al : Autoimmune polyendocrine syndrome type 1 in Norway : phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 92 : 595-603, 2007.
PubMed
12) Blomhoff A, et al : Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J Clin Endocrinol Metab 89 : 3474-3476, 2004.
 
13) Betterle C, et al : I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-s pecific autoimmune diseases : markers of low progression to clinical Addison's disease. J Clin Endocrinol Metab 82 : 932-938, 1997.
 
14) Coco G, et al : Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab 91 : 1637-1645, 2006.
 
P.237 掲載の参考文献
1) 川崎英二ほか : 急性発症1型糖尿病の診断基準 (2012) の策定-1型糖尿病調査研究委員会 (劇症および急性発症1型糖尿病分科会) 報告-. 糖尿病 56 : 584-589, 2013.
 
2) DIAMOND Project Group : Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 23 : 857-866, 2006.
PubMed
3) Japan IDDM Epidemiology Study Group : Lack of regional variation in IDDM risk in Japan. Diabetes Care 16 : 796-800, 1993.
 
4) Kida K, et al : Incidence of Type 1 diabetes mellitus in children aged 0-14 in Japan, 1986-1990, including an analysis for seasonality of onset and month of birth : JDS study. The Data Committee for Childhood Diabetes of the Japan Diabetes Society (JDS). Diabet Med 17 : 59-63, 2000.
 
5) Davis JL, et al : A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371 : 130-136, 1994.
 
6) Sugihara S, et al : HLA-class II and class I genotypes among Japanese children with Type 1A diabetes and their families. Pediatr Diabetes 13 : 33-44, 2012.
 
7) 永淵正法 : 糖尿病発症に関わるウイルス感染症. 月刊糖尿病 1 : 144-145, 2009.
 
8) Kotani Y, et al : Relatively small birth size and accelerated early growth of Japanese type 1 diabetic children with younger onset. Clin Pediatr Endocrinol 15 : 73-78, 2006.
PubMed
9) 田中昌一郎ほか : 緩徐進行1型糖尿病 (SPIDDM) の診断基準 (2012) -1型糖尿病調査研究委員会 (緩徐進行1型糖尿病分科会)報告-. 糖尿病 56 : 590-597, 2013.
 
10) 今川彰久ほか : 1型糖尿病調査研究委員会報告-劇症1型糖尿病の新しい診断基準 (2012). 糖尿病 55 : 815-820, 2012.
 
11) The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
 
12) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group : Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 : 381-389, 2000.
PubMed
13) Maruyama T, et al : Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93 : 2115-2121, 2008.
PubMed
14) Diabetes Epidemiology Research International Mortality Study Group : International evaluation of cau se-specific mortality and IDDM. Diabetes Care 14 : 55-60, 1991.
 
15) Asao K, et al : Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 26 : 2037-2042, 2003.
PubMed
P.242 掲載の参考文献
1) Hirata Y, et al : Insulin autoimmunity in a case of spontaneous hypoglycemia. J Jpn Diabetes Soc 13 : 312-320, 1970.
 
2) Uchigata Y, et al : Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 339 : 393-395, 1992.
PubMed
3) Yao K, et al : Human insulin-specific IgG antibody and hypoglycemic attacks after the injection of gold thioglucose. J Endocrinol Invest 15 : 43-47, 1992.
 
4) Uchigata Y, et al : Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata Disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol 61 : 154-157, 2000.
PubMed
5) Eguchi Y, et al : Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata Disease). Autoimmunity 19 : 279-284, 1994.
 
6) Uchigata Y, et al : Differential immunogenetic determimants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes 44 : 1227-1232, 1995.
 
7) Takayama-Hasumi S, et al : Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan. Diabetes Res Clin Pract 10 : 211-214, 1990.
PubMed
8) Uchigata Y, et al : Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract 83 : e19-20, 2009.
PubMed
9) 山口実菜ほか : ブシラミンによって発症したと考えられるインスリン自己免疫症候群の一例. 糖尿病 54 : 698-701, 2011.
 
P.246 掲載の参考文献
1) Kahn CR, et al : The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294 : 739-745, 1976.
 
2) Karlsson FA, et al : Desensitization of the insulin receptor at an early postreceptor step by prolonged exposure to antireceptor antibody. Proc Natl Acad Sci USA 76 : 809-813, 1979.
PubMed
3) Grunfeld C, et al : Autoantibodies against the insulin receptor. Dissociation of the acute effects of the antibodies from the desensitization seen with prolonged exposure. Diabetes 34 : 205-211, 1985.
PubMed
4) Fujita N, et al : Decrease in the insulin receptor protein level by anti-insulin receptor antibodies : roles of tyrosine kinase activity and receptor internalization. Acta Diabetol 39 : 221-227, 2002.
PubMed
5) De Pirro R, et al : Characterization of the serum from a patient with insulin resistance and hypoglycemia. Evidence for multiple populations of insulin receptor antibodies with different receptor binding and insulin-mimicking activities. Diabetes 33 : 301-304, 1984.
PubMed
6) Yamasaki H. et al : Anti-insulin receptor autoantibodies in a patient with type B insulin resistance and fasting hypoglycemia. Acta Diabetol 37 : 189-196, 2000.
 
7) Tsushima T, et al : Demonstration of heterogenelty of autoantibodies to insulin receptors in type B insulin resistance by isoelectric focusing. Diabetes 38 : 1090-1096, 1989.
 
8) Arioglu E, et al : Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance) : a 28-year perspective. Medicine (Baltimore) 81 : 87-100, 2002.
PubMed
9) 村上敦子ほか : 全身性エリテマトーデスに合併し, 重症の低血糖発作をきたしたインスリン受容体異常症B型の1例. 糖尿病 46 : 527-532, 2003.
 
10) 鴫原奈弓ほか : 重症の低血糖発作で発症し, SLEを合併したインスリン受容体異常症B型の1例. Diabetes Journal : 糖尿病と代謝 37 : 104-108, 2009.
 
11) Zhang S, et al : Type B insulin resistance syndrome induced by systemic lupus erythematosus and successfully treated with intravenous immunoglobulin : case report and systematic review. Clin Rheumatol 32 : 181-188, 2013.
PubMed
12) Lupsa BC, et al : Autoimmune forms of hypoglycemia. Medicine (Baltimore) 88 : 141-153, 2009.
PubMed
13) Semple RK, et al : Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 56 : 1712-1717, 2007.
PubMed
14) Imai J, et al : Eradication of insulin resistance. Lancet 374 : 264, 2009.
PubMed
15) Braund WJ, et al : Autoimmunity to insulin receptor and hypoglycaemia in patient with Hodgkin's disease. Lancet 1 : 237-240, 1987.
PubMed
16) 厚生省特定疾患ホルモン受容体機構異常調査研究班 : 平成7年度総括研究事業報告書.
 
17) 藤田成裕ほか : 3か月で寛解した全身性エリテマトーデス合併インスリン抵抗症B型の1例. 糖尿病 43 : 1077-1083, 2000.
 
18) Kawashiri SY, et al : Type B insulin resistance complicated with systemic lupus erythematosus. Intern Med 49 : 487-490, 2010.
PubMed
19) Malek R, et al : Treatment of type B insulin resistance : a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab 95 : 3641-3647, 2010.
PubMed
20) 堀江一郎ほか : 異なった治療反応性を呈したSLE合併インスリン受容体異常症B型の2例. 糖尿病 52 : 957-963, 2009.
 
21) 古川健亮ほか : Insulin-like growth factor-1 (IGF-1) が奏効したインスリン受容体異常症B型の1例. 糖尿病 51 : 629-634, 2008.
 
P.250 掲載の参考文献
1) Neufeld M, et al : Autoimmune polyglandular syndromes. Pediatr Ann 9 : 154-162, 1980.
PubMed
2) Peterson P, Peltonen L : Autoimmune polyendocrinopathy syndrome type 1 (APS1) and AIRE gene : new views on molecular basis of autoimmunity. J Autoimmun 25 : 49-55, 2005.
PubMed
3) Neufeld M, et al : Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 60 : 355-362, 1980.
 
4) Obermayer-straub P, Manns MP : Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol 12 : 293-315, 1998.
PubMed
5) Nagamine L, et al : Positional cloning of the APECED gene. Nat Genet 17 : 393-398, 1997.
 
6) Kurisaki H, et al : Autoimmune gastro-pancreatitis with anti-protein disulfide isomerase-associated 2 autoantibody in Aire-deficient BALB/cAnN mice. PLoS One 8 : 1-8, 2013.
 
7) Nagafuchi S, et al : Autoimmune regulator (AIRE) gene is expressed in human activated CD4+ T-cells and regulated by mitogen-activated protein kinase pathway. Micobiol Immunol 50 (12) : 979-987, 2006.
PubMed
8) Kahaly GJ : Polyglandular autoimmune syndromes. Eur J Endocrinol 161 : 11-20, 2009.
PubMed
9) Cutolo M : Autoimmune polyendocrine syndromes. Autoimmun Rev 13 : 85-89, 2014.
PubMed
10) Cervato S, et al : Evaluation of the autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermaLdystrophy (APECED) and in their relatives. Clin Endocrinol 70 : 421-428, 2009.
 
11) Scott HS, et al : Common mutations in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients of different origins. Mol Endocrinol 12 : 1112-1119, 1998.
PubMed
12) Kogawa K, et al : Distinct clinical phenotype and immunoreactivity in Japanese siblings with autoimmune polyglandular syndrome type 1 (APS-1) associated with compound heterozygous novel AIRE gene mutations. Clin Immunol 103 : 277-283, 2002.
PubMed
13) Matsumoto M : Contrasting models for the roles of Nre in the differentiation program of epithelial cells in the thymic medulla. Eur J Immunol 41 : 12-17, 2011.
 
14) Matsuo T, et al : Regulation of human autoimmune regulator (AIRE) gene translation by miR-220b. Gene 530 (1) : 19-25, 2013.
 
15) Kisand K, Peterson P : Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy : known and novel aspects of the syndrome. Ann N Y Acad Sci 1246 : 77-91, 2011.
PubMed
P.257 掲載の参考文献
1) 島津章 : 自己免疫性視床下部下垂体炎. 別冊日本臨牀 内分泌症候群 (第2版), p 37-40, 日本臨牀社, 2006.
 
2) Caturegli P, et al : Autoimmune hypophysitis. Endocr Rev 26 : 599-614, 2005.
PubMed
3) Imura H, et al : Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 329 : 683-689, 1993.
PubMed
4) Caturegli P, Iwama S : From Japan with love : another tessera in the hypophysitis mosaic. J Clin Endocrinol Metab 98 : 1865-1868, 2013.
PubMed
5) Mirocha S, et al : T regulatory cells distinguish tWo types of primary hypophysitis. Clin Exp Immunol 155 : 403-411, 2008.
 
6) Tzou SC, et al : Autoimmune hypophysitis of SJL mice : clinical insights from a new animal model. Endocrinology 149 : 3461-3469, 2008.
PubMed
7) Iwama S, et al : Rabphilin-3A as a targeted autoantigen in lymphocytic infundibulo-neurohypophysitis. J Clin Endocrinol Metab 100 : E946-E954, 2015.
PubMed
8) Iwama S, et al : Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6 : 230ra45, 2014.
PubMed
9) Bellastella G, et al : Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up. J Clin Endocrinol Metab 95 : 3750-3757, 2010.
 
10) Yamamoto M, et al : Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 121 : 113-119, 2011.
PubMed
11) Kristof RA, et al : Lymphocytic hypophysitis : non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? J Neurol Neurosurg Psychiatry 67 : 398-402, 1999.
PubMed
12) Shimatsu A, et al : Pituitary and stalk lesions (infundibulo-hypophysitis) associated with immunoglobulin G4-related systemic disease : an emerging clinical entity. Endocr J 56 : 1033-1041, 2009.
PubMed
13) Leporati P, et al : IgG4-related hypophysitis : anew addition to the hypophysitis spectrum. J Clin Endocrinol Metab 96 : 1971-1980, 2011.
 
14) 島津章 : IgG4関連 (漏斗) 下垂体炎. 内分泌・糖尿病・代謝内科 40 : 356-361, 2015.
 
P.262 掲載の参考文献
1) Umehara H, et al : A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol 22 (1) : 1-14, 2012.
PubMed
2) Komatsu K et al : High prevalence of hypothyroidism in patients with autoimmune pancreatitis. Dig Dis Sci 50 (6) : 1052-1057, 2005.
PubMed
3) Sah RP, Chari ST : Clinical hypothyroidism in autoimmune pancreatitis. Pancreas 39 (7) : 1114-1116, 2010.
PubMed
4) 遠藤佑香ほか : 自己免疫性膵炎における甲状腺機能の検討. 日消誌 111 (Suppl-2) : 957, 2014.
Medical*Online
5) 平野賢二ほか : 自己免疫性膵炎の膵外病変. 胆と膵 26 (9) : 761-768, 2005.
Medical*Online
6) Watanabe T, et al : Clinical features of a new disease concept, IgG4-related thyroiditis. Scand J Rheumatol 42 (4) : 325-330, 2013.
PubMed
7) 氷見徹夫ほか : 耳鼻咽喉科領域関連のIgG4関連疾患. 日耳鼻会報 117 (12) : 1438-1447, 2014.
 
8) Hashimoto H : Zur Kenntnis der lymphomatosen Veranderung der Schilddrtise (Struma lymphomatosa). Archiv fur klinische Chirurgie 97 : 219-248, 1912.
 
9) Li Y, et al : Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathol Int 59 (9) : 636-641, 2009.
 
10) Li Y, et al : Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease. Mod Pathol 25 (8) : 1086-1097, 2012.
 
11) Poplawska-Kita A, et al : High Serum IgG4 Concentrations in Patients With Hashimoto's Thyroiditis. Int J Endocrinol 2015 : 706843, 2015. doi : 10.1155/2015/706843. Epub 2015 Feb 16.
 
12) Riedel BMCL : Die chronische, zur Bildung eisenharter Tumoren fuehrende Entzundung der Schildduese. Verhandlungen der Deutschen Gesellschaft fur Chirurgie 25 : 101-105, 1896.
 
13) Dahlgren M, et al : Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 62 (9) : 1312-1318, 2010.
 
14) 亀山香織ほか : Riedel甲状腺炎の病理. 日内分泌会誌 85 (2) : 762, 2009.
Medical*Online
15) Takeshima K, et al : Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications. Thyroid 24 (4) : 736-743, 2014.
PubMed
P.266 掲載の参考文献
1) Hamano H, et al : High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344 : 732-738, 2001.
PubMed
2) 岡崎和一ほか : IgG4関連疾患包括診断基準 2011. 日内会誌 101 : 795-804, 2012.
 
3) Kawano M, et al : Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol 15 : 615-626, 2011.
PubMed
4) Zen Y, et al : Retroperitoneal fibrosis : a clinicopathologic study with respect to immunoglobulin G4. Am J Pathol 33 : 1833-1839, 2009.
 
5) Yoshimura Y, et al : IgG4-associated prostatitis complicating autoimmune pancreatitis. Intern Med 45 : 897-901, 2006.
PubMed
6) Nishimori I, et al : IgG4-related autoimmune prostatitis : two cases with or without autoimmune pancreatitis. Intern Med 46 : 1983-1989, 2007.
PubMed
7) Hart PA, et al : IgG4-related prostatitis : a rare cause of steroid-responsive obstructive urinary symptoms. Int J Urol 20 : 132-134, 2013.
PubMed
8) Buijs J, et al : Immunoglobulin G4-related prostatitis : a case-control study focusing on clinical and pathologic characteristics. Urology 83 (3) : 521-526, 2014.
PubMed
9) 中井靖ほか : 後腹膜線維症を伴ったIgG4関連疾患による前立腺炎の1例. 泌尿紀要 59 : 781-784, 2013.
 
10) Umehara H, et al : A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol 22 (1) : 1-14, 2012.
PubMed
11) Umehara H, et al : Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22 (1) : 21-30, 2012.
PubMed
12) Uchiyama-Tanaka Y, et al : Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis. Am J Kidney Dis 43 : e18-25, 2004.
PubMed
13) Fujinaga Y, et al : Characteristic findings in images of extra-pancreatic lesions associated with autoimmune pancreatitis. Eur J Radiol 76 : 228-238, 2010.
PubMed
14) Pipitone N, et al : Role of 18F-fluorodeoxyglucose positron emission tomography in the workup of retroperitoneal fibrosis. Clin Exp Rheumatol 29 (1 Suppl 64) : S72-78, 2011.
 
15) Uehara T, et al : Autoimmune pancreatitis-associated prostatitis : distinct clinicopathological entity. Pathol Int 58 : 118-125, 2008.
PubMed
P.270 掲載の参考文献
1) Evans RS, et al : Primary thrombocytopenic purpura and acquired hemolytic anemia ; evidence for a common etiology. AMA Arch Intern Med 87 : 48-65, 1951.
PubMed
2) Norton A, Roberts I : Management of Evans syndrome. Br J Haematol 132 : 125-137, 2006.
PubMed
3) Costallat GL, et al : Evans syndrome and systemic lupus erythematosus : clinical presentation and outcome. Joint Bone Spine 79 : 362-364, 2012.
PubMed
4) Silverstein MN, Heck FJ : Acquired hemolytic anemia and associated thrombocytopenic purpura : with special reference to Evans's yndrome. Proc Staiif Meet Mayo Clin 28 : 122-128, 1962.
 
5) Pui CH, et al : Evans syndrome in childhood. J Pediatr 97 : 754-758, 1980.
PubMed
6) 佐藤恵理子, 押美和夫 : Evans症候群. 別冊日本臨牀 免疫症候群 (上巻), p 137-139, 日本臨牀社, 2000.
 
7) Kakaiya RM, et al : Nature of platelet antibody in Evans syndrome : acase report. Ann Clin Lab Sci 11 : 511-515, 1981.
 
8) Pegels JG, et al : The Evans syndrome : characterization of the responsible autoantibodies. Br J Haematol 51 : 445-450, 1982.
PubMed
9) Wang W, et al : Immunoregulatory abnormalities in Evans syndrome. Am J Hematol 15 : 381-390, 1983.
PubMed
10) Karakantza M, et al : Th1 and Th2 cytokines in a patient with Evans's yndrome and profound lymphopenia. Br J Haematol 110 : 968-970, 2000.
 
11) Teachey DT, Felix CA : Development of cold agglutinin autoimmune hemolytic anemia during treatment for pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol 27 : 397-399, 2005.
PubMed
12) Fagiolo E : Platelet and leukocyte antibodies in autoimmune hemolytic anemia. Acta Haematol 56 : 97-106, 1976.
PubMed
13) Scaradavou A, Bussel J : Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol 17 : 290-295, 1995.